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 Abstract 
 
Skeletal muscle regeneration and the role of Sirtuin 1 
 
Brian T. Bennett 
 
The main objective of this master’s thesis project was to elucidate the role of the deacetylase 
Sirtuin 1 (Sirt1) in skeletal muscle regeneration.  We developed two specific aims to accomplish this task, 
which involved separate studies in order to study the effects of Sirt1 in multiple models of regeneration.  
The results from these studies may potentially lead to the development of novel therapies to treat 
various clinical conditions which require muscle regeneration. 
 Specific aim 1 utilized resveratrol, a Sirt1 activator, as a supplement to improve muscle 
regeneration following a period of disuse in aged animals.  Aged Fisher 344 × Brown Norway rats were 
hindlimb suspended for a total of fourteen days (HS), whereupon one-half of the animals were sacrificed 
and the remainder were unloaded and allowed a fourteen day recovery period of normal ambulation 
(R), at which point they were sacrificed.  During the experimental period, each rat received either 1ml of 
resveratrol (125 mg/kg) or 1ml of carboxymethylcellulose dissolved in distilled water (vehicle) via oral 
gavage at approximately the same time each morning.  Additionally, a group of vehicle treated animals 
maintained normal ambulation throughout the protocol and served as cage controls for the suspended 
animals.   
 Resveratrol was not able to attenuate losses in either body or muscle wet weights following HS 
and did not provide any additional benefits to these measures during the R period.  Surprisingly, 
resveratrol treated animals did not fare as well on a fatigue protocol and few differences were observed 
upon examination of a force-frequency curve.  However, fiber type analyses revealed a shift towards 
increased type IIA myosin heavy chain (MyHC) fibers following HS.  Resveratrol also attenuated 
decreases in fiber area in type IIA MyHC fibers following HS and in both type IIA and IIB MyHC fibers 
following the R period. 
 Our results from this study indicate a potential for the use of resveratrol in benefitting skeletal 
muscle regeneration in aged populations following periods of disuse such as extended hospitalizations.  
Although resveratrol was unable to maintain muscle function as determined by the force characteristics, 
it clearly benefitted muscle fiber size which is important in this population as the elderly have 
diminished regenerative abilities.  Future research should be aimed at determining the optimal dosage 
to fully maximize the benefits of this supplement in skeletal muscle regeneration.   
 Specific aim 2 attempted to establish the role of Sirt1 in muscle regeneration using transgenic 
mice which either overexpressed (Sirt1+/+) or had diminished Sirt1 expression (Sirt1-/-) in the skeletal 
muscles.  Tibialis anterior (TA) muscles were examined either 3 or 7 days following a cardiotoxin (CTX) 
injection in the animals left TA muscles.  The right TA muscles were injected with sterile PBS and were 
used as intranimal controls for the CTX administration. 
 Increasing Sirt1 expression did not have an effect on muscle mass or fiber area at either 3 or 7 
days.  However, increasing its expression attenuated decreases in maximal tetanic force production at 
both 3 and 7 days post-injury while there were no differences observed in these forces in the Sirt1-/- 
animals.  There were no differences observed between any of the groups in BrdU incorporation and 
furthermore, in apoptosis as determined via TUNEL staining. 
 Results from this study indicate that Sirt1 may not play a significant role in muscle mass or fiber 
area during the early stages of muscle regeneration.  However, increasing Sirt1 expression was 
 beneficial in that it improved muscle force characteristics which would suggest improved functional 
recovery in these animals.  Therefore, although inconclusive, increasing Sirt1 expression may be 
beneficial at improving skeletal muscle regeneration in that it may reduce functional impairments in 
muscle viability.  Future research may thus be directed at developing therapies to exploit these benefits 
and be applied toward clinical populations which require skeletal muscle regeneration.
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Sarcopenia is the involuntary loss of muscle mass and physical function as a 
consequence of aging (36).  Throughout the decades, humans gradually lose increasing 
amounts of muscle mass, and concomitantly strength.  From the age of near 50 and onwards, 
muscle strength declines approximately 12%-15% each decade (36).  Sarcopenia increases the 
susceptibility to falls and is also associated with increased risk of morbidity and mortality (46).  
This can severely limit functional independence and therefore, quality of life.  Extended 
hospitalization and other forms of disuse may further exacerbate these complications.  Annually, 
billions of dollars are spent on healthcare costs that can be directly attributed to this condition.  
While multifactorial in nature, the etiology of sarcopenia may be due in part to increased 
apoptotic signaling with advancing age, increased reactive oxygen species (ROS) production, 
dysfunctional mitochondrion, and impaired muscle regeneration following injury or disuse.   
Implicated in the growth and regeneration of skeletal muscle, muscle stem cells (i.e., 
satellite cells) show a decreased efficiency in their ability to proliferate and/or differentiate with 
advancing age (12; 27).  Normally quiescent, satellite cells are activated in response to injury 
and/or stress and subsequently proliferate, differentiate, and grow in order to repair damaged 
muscle tissue (59; 211).  With increasing age, satellite cell numbers gradually decline, possibly 
leading to the impaired regenerative ability of muscle observed in many older adults (12; 61).  
Moreover, satellite cell function is perturbed in many myopathies, such as the muscular 
dystrophies, greatly impairing the maintenance and repair of damaged muscle.  Thus, a better 
understanding of the mechanisms behind satellite cell activation and function is required in 
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order to develop novel therapies aimed at reducing skeletal muscle degeneration which occurs 
in aging and myopathic conditions. 
Activation of silent mating type information regulation homolog 1, or Sirtuin 1 (Sirt1), has 
been shown to be beneficial in neurodegenerative, metabolic, inflammatory, and neoplastic 
diseases, and has also been shown to increase lifespan in several organisms (75; 102; 196).  
Sirt1 appears to play an important role in the regulation of oxidative stress, apoptosis, 
mitochondrial biogenesis, insulin sensitivity, and satellite cell proliferation (43; 242).  Typical 
regimens of increasing Sirt1 activity levels experimentally include caloric restriction and 
supplementation of the naturally occurring polyphenol, resveratrol. Our preliminary data indicate 
that NAD⁺  biosynthesis, Sirt1 activity, mitochondrial biogenesis, and satellite cell function are 
impaired with aging, and also in aged muscles following a period of disuse (123).  Furthermore, 
nuclear apoptosis also appears to play a role in sarcopenia.  Apoptosis, particularly through the 
mitochondrial pathway, is accelerated in aging and disuse.  However, the role of Sirt1 and its 
implications in the treatment of sarcopenia and muscle regeneration have not been fully 
established.  Recent work from our lab has shown that low levels of resveratrol, a Sirt1 
activator, could effectively reduce levels of oxidative stress in hindlimb suspended animals, but 
was unable to attenuate muscle losses in these animals (123).  What is not known is if a higher 
dose of resveratrol, and therefore increased Sirt1 activation, will provide protection against 
muscle atrophy following a period of muscular disuse and subsequently improve the 
regenerative ability of these muscles through the activation of satellite cells.  Furthermore, the 
role of Sirt1 expression in muscle regeneration has yet to be directly examined.   
The main objective of this project is to examine the role of Sirt1 expression on skeletal 
muscle regeneration and to subsequently use this information to improve muscle growth and 
functional recovery in various physiological conditions.  Our central hypothesis is that increasing 
Sirt1 activity will improve skeletal muscle regeneration (i.e., strength and/or size) following a 
period of disuse in aged animals, and also in response to an acute cardiotoxin injury.  We will 
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use a combination of nutritional and genetic approaches to regulate Sirt1 activity in rodent 
muscles. 
Specific aim #1:  Establish the efficacy of resveratrol, a Sirt1 activator, to improve 
muscle regeneration after disuse. 
Our working hypothesis is that increasing Sirt1 activity through resveratrol 
 supplementation will reduce mitochondrial-associated apoptosis, preserve muscle mass, 
 and increase activation of muscle satellite cells during a period of reloading following 
 disuse in aged rats.  This will lead to improvements in muscle morphological and/or 
 functional characteristics. 
 
Specific aim #2:  Define the role of Sirt1 in improving skeletal muscle regeneration 
following injury. 
Our working hypothesis is that Sirt1 will improve muscle regeneration (i.e., strength 
 and/or size) following an acute cardiotoxin injury through an increase in satellite cell 
 activation and proliferation. This will hasten the recovery process of the injured muscles. 
 
Study Limitations 
 Each of our two specific aims will have certain a priori limitations that we will have to be 
mindful of while conducting the research.  In our first specific aim we utilize aged animals, which 
present a unique set of problems when attempting to examine muscle regeneration.  It is well 
known that aged organisms have a reduced capacity to regenerate bodily tissues, due to 
decreased functional abilities of their intrinsic stem cells or in the environment in which these 
stem cells reside.  Regardless of the reason, the potential conflict with this diminished 
regenerative ability is that it can be difficult to determine if a given intervention is effective, as 
any benefits will be much less noticeable than in a younger organism.  Thus, even if resveratrol 
appears to be beneficial in our model, the blunted regenerative response of the aged animals 
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may prevent any of these benefits from becoming statistically significant.  Another potential 
problem that we may have with these animals is their age-associated increase in morbidity and 
mortality.  It is possible that some of these animals will die during the course of the study or 
develop systemic conditions which could unintentionally affect our findings.  However, it is 
important that we use aged animals in this study as it is the aging human population which is 
more susceptible to similar periods of disuse and immobilization, such as extended hospital 
stays, and for whom there needs to be novel therapies developed to enable more efficacious 
recoveries. 
 The limitations of our second specific aim are less visibly obvious.  In analyzing the 
muscle regeneration of our transgenic animals, we are only concerned about the effects of Sirt1 
expression on the general regeneration process.  However, the effects of Sirt1 are mediated by 
its activation of several downstream targets.  This being the case, we are only attempting to 
define the general role of Sirt1 in regeneration, and will not attempt to examine each individual 
downstream target to determine which specific pathway may be inducing these potential effects.  
This is important, as it must first be established whether Sirt1 expression has any effects on 
skeletal muscle regeneration before attempting to distinguish which pathways Sirt1 is exerting 
its influence upon to initiate these effects.  Thus, if our results from this study indicate that 
increasing Sirt1 expression is beneficial to muscle regeneration as hypothesized, future studies 
could then be directed toward deciphering these individual pathways and proteins which are 
recruited and enable the beneficial effects.  However, it must be restated that the aim of this 
current study is attempting only to establish whether Sirt1 expression in general has any 





Background and Significance 
 
2.1  Skeletal muscle 
 
Skeletal muscle comprises 40-50% of the total mass in the average young adult human.  
It is crucial for locomotion, proper metabolism, generating heat during periods of cold stress, 
and the maintenance of posture (24; 131).  Skeletal muscle fibers are multinucleated and exhibit 
central nucleation on formation or repair from injury, but these nuclei later migrate to a 
subsarcolemmal position and are then considered to be myofibers (51; 114).  The myofiber is 
the basic structural element of skeletal muscle (234), and is formed from fused myoblasts.  The 
basic functional unit of skeletal muscle is the sarcomere, which lies within the myofiber and 
contains thin actin and thick myosin filaments which interact with each other upon 
neuromuscular stimulation (234).  These signals, carried by acetylcholine-induced action 
potentials, release calcium stored in the sarcoplasmic reticulum, causing the actin and myosin 
to alternately overlap and dissociate, decreasing the size of the sarcomere which is the source 
of muscle contraction (35; 229). 
Myosin composition.  Encompassing ~25% of the total skeletal muscle protein pool, 
myosin is the most abundant protein and consists of multiple myosin heavy chain (MyHC) 
isoforms (91).  Four MyHC isoforms have been identified in small mammals; MyHC type I, 
MyHC type IIA, MyHC type IIX, and MyHC type IIB myofibers (40).  Slow MyHC type I myofibers 
are resistant to fatigue, fast MyHC type IIA myofibers are moderately fatigue resistant, fast 
MyHC type IIB myofibers show no resistance to fatigue, and MyHC type IIX myofibers are an 
intermediate between MyHC type IIA and MyHC type IIB fibers (234).  A number of experiments 
on skinned muscle fibers have established the fiber types as I, IIA, IIX, and IIB (40).  Shortening 
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velocity and force are highest in type IIB fibers and lowest in type I fibers (29; 30).  While 
humans possess the gene for MyHC type IIB myofibers, the corresponding protein does not 
appear to be expressed (221; 247).  Thus, human skeletal muscle is only comprised of three 
pure fiber types (I, IIA, and IIX), and two additional hybrid types (I-IIA and IIAX) (28; 225; 250; 
251).  While skeletal muscle normally maintains a constant protein turnover with little 
physiologic impact, conditions such as aging, disease, or disuse may tilt this balance to favor 
catabolism, producing a variety of complications.  
 
2.2  Sarcopenia  
 
Sarcopenia is a multifactorial, involuntary loss of skeletal muscle mass and function (e.g. 
strength) which occurs as a consequence of aging (36; 67; 246).  Up to 15% of individuals over 
the age of 65 and as much as 50% of those over the age of 80 are thought to suffer from 
sarcopenia (15).  Furthermore, it was estimated that the direct cost of healthcare attributed to 
sarcopenia in the United States in 2000 was $18.5 billion (127).  Currently, the primary cause of 
sarcopenia has not been well established.  However, as the definition implies, a multitude of 
factors have been implicated in reducing the quality of life and functionality of those afflicted with 
this condition. 
Muscle fiber and strength decline.  Defined as the maximal tetanic force (P0) 
produced per muscle fiber cross-sectional area (CSA), specific force (P0/CSA) is a widely used 
measure of relative muscular strength.  It has been shown that muscles in elderly individuals 
produce a lower specific force than do young control subjects (70; 141).  In general, muscle 
strength gradually decreases 12%-15% per decade beyond the age of 50, with a larger 
decrease seen after the age of 65 (152; 167; 177).  Furthermore, there is a preferential loss of 
the larger diameter type II fibers as compared to type I fibers with increasing age, which may be 
caused by a decrease in high-intensity activities needed to stimulate these fibers (241).  The 
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loss in muscle mass may also be due to an increase in apoptotic signaling that is seen in older 
adults (144; 165; 193).  Subsequently, these two variables lead to an approximately 50% 
decline in the number of total muscle fibers and a 30% loss in muscle mass between the ages 
of 20 and 80 (81; 87).  Therefore, it may not be surprising that sarcopenia has been shown to be 
predictive of falls (46), and also leads to increased mortality due to diminished muscle strength 
(168; 180).   
Additional factors.  In older age, fast motor units become denervated and subsequently 
reinnervated with slow motor units, leading to increased muscle fatigability during periods of 
high-intensity work (85).  In moderately active 75-year old males, sarcopenia may account for 
reductions in fiber pennation angle, maximal voluntary force output, and relaxation rate of the 
muscle (126; 132; 178).  Hormonal factors may also play a role in the development of 
sarcopenia.  Growth hormone (GH), insulin-like growth factor (IGF-1), and androgens, which 
function in the growth and development of skeletal muscle, all appear to decrease with older 
age (36). 
 
2.3  Mitochondrial Function and Apoptosis 
 
Another factor that appears to be detrimental to skeletal muscle and contribute to 
nuclear apoptosis are dysfunctional mitochondrion.  Mitochondria, deemed the “powerhouse of 
the cell”, are crucial for producing adenosine triphosphate (ATP), a ready-usable energy 
substrate for multiple biological processes (140).   
The volume density of mitochondria is fundamental in the ability to sustain a steady-state 
of muscular work (48).  Several studies have shown that mitochondrial content decreases with 
age (63; 111; 166; 203; 216; 248).  This may be due in part to a reduction in several mRNA 
transcripts for genes encoding mitochondrial proteins (13; 38; 248).  Furthermore, there appears 
to be a decrease in the function of these remaining mitochondria (22; 140; 187; 191; 216).  
8 
 
However, it is interesting to note that a study by Rasmussen et al. (197) concluded that the 
reduced mitochondrial capacity is associated with reduced exercise, and is not due to 
chronological age.  Energy defects stemming from impaired or dysfunctional mitochondria have 
been implicated in forms of movement disorders, deafness, blindness, dementias, 
cardiomyopathy, myopathy, renal dysfunction, neurodegenerative disorders, metabolic 
disorders, cancer, and aging (76; 244).  Regardless of the cause, it is clear that with aging 
comes a reduction in the total number and functionality of mitochondria, possibly leading to 
muscular atrophy and impaired regeneration.  
Oxidative stress.  First described by Denham Harmon, the free radical theory of aging 
suggested that the production of free radicals as a byproduct of normal mitochondrial respiration 
would play a major role in the process of aging (103).  Recent work has shown that reactive 
oxygen species (ROS) such as peroxides, which are not free radicals, also cause damage to 
the cells via oxidative stress (23).  Therefore, Harmon’s original theory has been revised to 
include these developments, and is now referred to as the Oxidative Stress Theory of Aging 
(23).  Oxidative stress has thus been defined as the ‘imbalance between oxidants and 
antioxidants in favor of the oxidants, potentially leading to damage (217). 
While initial assessments concluded that 2-5% of oxygen used during respiration is 
converted to the ROS superoxide anion (31; 155), more recent studies have shown that ROS 
production may be closer to 0.15%  (223).  Originally thought to be only harmful to the cell, it 
has now been shown that ROS are important signaling molecules that function in gene 
expression as well as cell and tissue homeostasis (82; 125).  Redox signaling associated with 
ROS has been associated with maintenance of force production during contractions, insulin 
signaling, and glucose uptake (124).  ROS are also thought to be involved with the mediation of 
skeletal muscle adaptation due to contractile activity through the activation of redox-sensitive 
transcription factors (125; 202).  Furthermore, ROS have been implicated in the activation of 
multiple signaling cascades. 
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 Mitochondrial associated apoptosis.  Losses in muscle mass due to disuse atrophy 
and sarcopenia may be attributed to an increase in apoptotic signaling.  Apoptosis is a tightly 
regulated process causing cellular destruction without damaging surrounding tissues nor 
promoting inflammation (133).  It is necessary for a variety of biological processes including 
cellular turnover, tissue homeostasis, and embryogenesis (133).  While the apoptotic response 
may not target whole fibers, it may result in the selective elimination of individual myonuclei 
(84).  The mitochondrion is considered to be the vehicle through which the integration of 
apoptotic signaling and the induction of apoptosis is initiated (2).  While usually present in 
organisms as inactive zymogens (procaspases), activated cysteine-aspartic proteases 
(caspases) are responsible for carrying out the actual cellular decomposition (106).   These 
caspases may be activated through both the intrinsic and extrinsic pathways (71).  Of particular 
relevance is the mitochondrial associated intrinsic pathway of apoptosis.  Mitochondria are 
considered to be the prominent regulator of the intrinsic apoptotic pathway as they house a 
variety of pro- and anti-apoptotic factors (128).  Cytochrome c, a small electron carrier 
associated with the inner mitochondrial membrane, has been one of the most extensively 
studied mediators of apoptosis (162).  When the proper functioning of mitochondria is inhibited, 
cytochrome c is released into the cytoplasm where it associates with apoptotic protease-
activating factor-1 (Apaf-1), dATP, and procaspase-9, which forms the apoptosome (128).  
Subsequently, the homo-oligomerization of procaspase-9 activates caspase-3, in turn initiating 
apoptosis (128). 
 Mitochondria also possess a caspase-independent apoptotic pathway.  This pathway is 
carried out by the apoptosis-inducing factor (AIF) as well as endonuclease G (EndoG) (240).  
AIF is released into the cytoplasm from the mitochondria, translocates to the nucleus, and then 
binds to DNA to initiate chromatin condensation (72).  It may also produce large-scale DNA 
fragmentation by forming an active DNase with cyclophilin A (39).  EndoG, on the other hand, is 
a mitochondrion-specific nuclease which is required for normal cell proliferation (113).  In 
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apoptotic situations, EndoG participates in oligonucleosomal DNA fragmentation when it is 
released from the mitochondria and enters the nucleus (150).   
 BCL-2 family regulation.  Required for the release of pro-apoptotic factors residing in 
the mitochondria, the mitochondrial outer membrane permeabilization (MOMP) is necessary for 
initiation of mitochondrial-associated apoptosis (55).  The integrity of the outer mitochondrial 
membrane (OMM) is influenced by the BCL-2 (B-cell lymphoma 2) family of proteins, which are 
considered either pro- (e.g. Bax, Bid, Bak, Bim) or anti-apoptotic (e.g. BCL-2, BCL-XL) (49).  
BCL-2 and BCL-XL inhibit the activity of Bax and/or Bak under homeostatic conditions (9).  It is 
thought that under apoptotic conditions, Bid and/or Bim, which are necessary for the activation 
of Bax and/or Bak, downregulate BCL-2 and BCL-XL activity and therefore initiate apoptosis 
(56).  Furthermore, while Bid can be activated by the cleavage of caspase-8, there can also be 
cross-talk between the extracellular and intracellular pathways of apoptosis (149).   
  
2.4  Satellite Cells 
 
 In addition to the problems associated with muscle atrophy due to disuse and 
immobilization, aged skeletal muscle also displays impaired regeneration.  This may be due in 
part to a reduction in satellite cell abundance with age.  Several studies have shown that 
following sexual maturity, satellite cell numbers begin a gradual descent (21; 50; 209).  First 
described in 1961 by Alexander Mauro, the satellite cell resides on the periphery of skeletal 
muscle fibers, between the sarcolemma and basal lamina (163).  Satellite cells were first shown 
to function as myoblasts in 1969 by Reznik, who was also the first to term them stem cells 
(200).  This was further supported by the work of Moss and Leblond, who showed that satellite 
cells become mitotically active and contribute nuclei to both damaged and growing myofibers 
(173; 174).  It was subsequently shown in 1977 that satellite cells, and not myofibers, contribute 
these nuclei to the regenerating skeletal muscle (222).  Satellite cells are therefore very 
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important, as they are a major source of skeletal myoblasts that repopulate damaged and 
growing post-natal skeletal muscle tissues and also have the ability to form new myofibers (17; 
59; 211). 
 Satellite cell provisions.  As a tissue-specific stem cell population, satellite cells must 
be able to provide differentiating progeny of which to fuse with new and damaged myofibers, 
and also have a mechanism capable of self-renewing the stem cell population.  For these to 
occur, a subpopulation of satellite cells must be able to stop itself from progressing down the 
myogenic lineage and revert back into quiescence, or, a subpopulation of these cells must 
divide asymmetrically, therefore forming both differentiating and stem cell progeny (182).  These 
mechanisms do not have to be mutually exclusive, and it has been suggested that each of these 
scenarios may occur in vivo (138; 260). 
 Satellite cell replenishment.  Upon activation, the majority of satellite cells begin 
expressing the myogenic regulatory factor MyoD, and upon differentiation, express myogenin 
(66; 135; 260).  In a study by Zammit et al., it was shown that a subset of activated satellite cells 
(i.e. MyoD⁺ ) switches off the marker while retaining Pax7 expression and returning to a 
quiescent state (260).  This suggests that satellite cells replenish their quiescent pool through 
the reversal of the myogenic lineage paradigm.  However, multiple studies have shown that 
satellite cells may divide asymmetrically, giving rise to differential daughter cells that help to re-
establish the quiescent pool (62; 138; 215).  Furthermore, Shinin et al. suggest that satellite 
cells are capable of asymmetric division in which one of the cells retains the maternal ‘immortal’ 
DNA strand (215), a model proposed by John Cairns in 1975 (37).   
 In Cairns immortal strand hypothesis, the true stem cell, when dividing, retains the 
template strand of DNA, while the newly synthesized strand would be inherited by the cell 
destined for differentiation, therefore reducing the likelihood for a build-up of potentially 
oncogenic mutations in the stem cell population (37).  However, it has been shown that 
heterogeneity exists within the satellite cell population, with only a portion of cells which can 
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undergo asymmetric divisions and retain immortal DNA strands in this manner, suggesting that 
not all Pax7+ satellite cells on adult myofibers have equivalent lineages (137; 215).  Further 
supporting this, it was shown that satellite cells that remain in contact with the basal lamina of 
the myofiber during asymmetric division will retain their stem cell function, while cells that lose 
contact with the basal lamina during this period initiate Myf5 expression, which spurs 
differentiation (138).  This suggests that the niche environment of satellite cells plays an 
important role in their proliferative capacity. 
 Molecular markers of satellite cells.  Satellite cells have been shown to express a 
wide variety of molecular markers which enable their identification.  Among these are the cell-
adhesion protein M-cadherin, CD34, the myogenic regulatory factor myf5, Caveolin-1, 
Syndecan-3 and 4, and C-Met (6; 17; 64; 66; 120; 243).  Of greater importance, Pax7 is 
expressed in the nucleus of all quiescent adult satellite cells and appears to be vital for 
maintenance of the satellite cell population in adults (183; 211).  The ‘Paired Box’, or Pax, family 
of genes are transcription factors which are essential for embryonic development  (26; 159; 
239).  There are nine known Pax genes (Pax1-9) in mammals, which are subdivided into four 
groups based on genomic structure, sequence similarity, and function (245).  Forming one of 
these subgroups, Pax3 and Pax7 are homologous genes, but play different roles during 
embryological development (182).  Pax3, a paralogue of Pax7, is crucial for myogenesis in the 
developing embryo, demonstrated by Pax3 mutant mice which lack limb musculature (20; 93; 
228).  However, while both Pax3 and Pax7 are important in regulating myogenesis, Pax3 is 
downregulated before birth, suggesting that its role in adult tissues is limited (156).  Supporting 
this idea, it has been shown that most of the function of Pax3 can be replaced by Pax7 after 
birth (199).  Furthermore, Pax7-null mice progressively lose satellite cells in adulthood due to 
apoptosis, whether Pax3 is expressed or not, which implies that Pax3 is not able to replace 
Pax7 in vivo for the maintenance of satellite cell viability during adulthood (199).  Also, it has 
been shown that Pax7-/- mutant mice lack satellite cells and fail to grow or regenerate after birth, 
13 
 
subsequently dying within 2-3 weeks  (160; 211).  Moreover, multiple studies have shown that 
Pax7 is required for normal muscle regeneration, and regeneration is severely retarded in its 
absence or depression (147; 207).  
 Activation of satellite cells.  Following injury, multiple signals appear to activate 
satellite cells, which subsequently begin proliferating on the second day post-injury (57).  
Satellite cell activation requires sphingosine-1-phosphate on the inner side of the plasma 
membrane, and without its synthesis, satellite cells do not enter the cell cycle and regeneration 
is incomplete (176).  The production of nitric oxide (NO) through increased NO synthase (NOS) 
activity may also be important for satellite cell activation through activation of matrix 
metalloproteinases, which induce the release of hepatocyte growth factor (HGF) from the 
extracellular matrix  (232).  In turn, HGF binds to its receptor on satellite cells, c-Met, thus 
stimulating an activated satellite cell response (231).    
 Differentiation of satellite cells.  The switch from satellite cell proliferation to 
differentiation appears to be under the control of notch and Wnt signaling.  Following injury, 
sustained notch signaling is necessary for the expansion of the satellite cell progeny, while 
canonical Wnt signaling subsequently drives differentiation (32; 61; 62).  Defective notch 
signaling inhibits the self-renewal and proliferative properties of satellite cells, while notch 
signaling enhancement leads to increased regeneration in aged muscle (61; 138).  Increased 
Wnt signaling, on the other hand, appears to drive the differentiation of proliferating myoblasts 
(32).  The timing of this is crucial, as premature Wnt signaling leads to early differentiation and 
fusion of the myoblasts before the number of proliferating myoblasts are sufficient for proper 
regeneration (32).  However, the signaling of Wnt during muscle regeneration appears to be 
complex.  Acting through a non-canonical Wnt pathway and upregulated during regeneration, 
Wnt7a is necessary for the expansion of the satellite cell population during regeneration (142).  
Opposing the normal functions of Wnt signaling, Wnt7a does not affect the growth or 
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differentiation of myoblasts (57).  While overexpression of Wnt7a enhances regeneration, 
muscles lacking Wnt7a display a reduction in satellite cell number following regeneration (142). 
 MyoD expression.  Moving forward through the satellite cell regenerative process, the 
MyoD family regulators of muscle determination and differentiation (MRFs) are expressed in 
committed myogenic precursor cells.  Among these regulators are MyoD, Myf5, Mrf4, and 
myogenin (57).  In a study using a single-cell RT-PCR assay, activated satellite cells expressed 
both MyoD and Myf5 together, myogenin was expressed later in these cells, and many cells 
expressed all four MRFs simultaneously (66).  However, MyoD may be the most crucial 
regulator in the regenerative process.  In MyoD null satellite cells, myogenin is reduced and 
Mrf4 is totally absent, resulting in a severely blunted differentiation capacity (65).  Furthermore, 
in the absence of MyoD, there is a marked impairment in the regenerative ability of muscle due 
to perturbations in cell proliferation and differentiation levels (164).        
 Myogenin expression.  Lastly, skeletal muscle regeneration is aided through the 
expression of myogenin and MRF4.  While neither are required for satellite cell development or 
maintenance (90), the induction of myogenin is required for the formation of myotubes and 
fibers (143).  This was observed in mice with a post-natal recombination of myogenin which 
displayed reduced muscle mass, suggesting that the absence of myogenin prevented the 
skeletal myoblasts from contributing to post-natal muscle growth (134).  Thus, the induction of 
myogenin commits the cells to differentiate and subsequently grow. 
  
2.5  Muscle regeneration   
 
 While the degenerative and regenerative phases involved in skeletal muscle 
regeneration are essentially the same, the kinetics of these phases may be influenced by 
factors such as the severity of injury, the muscle injured, and also the animal model used (119; 
145; 170; 188).  To develop methods of studying muscle regeneration, the design of animal 
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models that are controlled and reproducible is necessary.  One of the easiest and most 
reproducible methods of inducing injury is the use of myotoxins, such as cardiotoxin (CTX), 
notexin (NTX), or bupivacaine (69; 96; 104).  Injected directly into the individual muscle of 
interest, these toxins have a wide range of biological activities and exert their effects in a very 
short manner.  CTX, a peptide isolated from snake venom, is a protein kinase C-specific 
inhibitor that appears to disrupt membrane organization, induce the depolarization and 
contraction of muscle cells, and will lyse various cell types (51).  Typically with this model, 
muscle degeneration is seen within a day of injection, myogenic cell differentiation is seen ~5-6 
days later, and normal histologically and morphologically mature muscle is restored after ~3-4 
weeks following the injury (51).  These rapid results, paired with a high degree of reproducibility, 
make the CTX model an excellent method for studying muscle regeneration. 
 Models of muscular disuse.  While the CTX protocol works very well, disuse and/or 
immobilization models may be more physiologically relevant for studying muscle regeneration.  
Actual muscle loss varies in relation to the mode of disuse/immobilization.  In the large leg 
muscles of humans, a head down bed rest position induces the greatest decreases in fiber CSA 
(5; 8; 19; 34; 74), with slightly smaller decreases seen following casting (109; 110; 129), 
followed closely behind by unilateral leg suspension and knee immobilization (45; 73; 78; 257).  
Also, it has been shown that muscle fibers experience greater losses in CSA than do whole 
muscles   (11; 109; 238; 257).  The common element binding these various modalities has been 
suggested to be due to both a reduction in net protein synthesis and also an increase in protein 
degradation (195; 235).  While slow type I fiber muscles experience greater atrophy than do fast 
type II fiber muscles in rodent models (25; 83; 97; 121), in humans this may not be true (11; 
238; 257).   
 Hindlimb suspension.  A widely used model of disuse for studying muscle atrophy and 
regeneration is hindlimb suspension (HS).  Originally developed by NASA in order to study the 
effects of spaceflight in a ground-based model, HS is a common technique used to study a 
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variety of skeletal muscle adaptations in response to disuse (100; 181; 201; 204; 233; 235).  
Generally, a rodent is suspended by its tail so that the hind limbs cannot reach the cage floor, 
but the animal is still free to move around its cage and groom itself (100).  A suspension period 
of fourteen days is typically sufficient to induce significant decreases in muscle mass in rodents 
(100; 218; 220; 252; 258).  Due to decreased signaling to the muscles, HS may inhibit 
mitochondrial biogenesis and/or increase apoptotic signaling (190).  Furthermore, HS has been 
shown to elicit a fiber type switch from slow to fast MyHC isoforms in response to the period of 
disuse (192; 224; 230).  To study the regenerative potential of the atrophied myofibers, a 
subsequent reloading period may be incorporated immediately following HS.  The HS protocol 
combined with this reloading period is very similar to the atrophy and regeneration of muscles in 
humans who undergo periods of immobilization such as bed rest.  This is noteworthy, as 34%-
50% of hospitalized elders undergo a decline in their functional status during the period between 
admission and discharge (118).  Thus, the HS model is a physiologically relevant paradigm to 
study the response of muscles to disuse in populations such as the elderly, who are increasingly 
prone to hospitalizations with advancing age (1; 98; 169).   
 
2.6  Sirtuin 1  
 
 Resveratrol as a Sirt1 activator.  Resveratrol (3,5,4’-trihydroxystilbene) is a naturally 
occurring phytoalexin that is found in high concentrations in the skin of red grapes, but is also 
found in mulberries, peanuts, pines, and root extracts of the weed Polygonum Cuspidatum (10; 
116).  The function of this compound in plants is to provide protection from fungal infections 
(146).  It consists of two isomers, trans-resveratrol and cis-resveratrol, of which the trans isomer 
is the more stable (213).  Trans to cis isomerization is induced by both UV light and high pH, 
while cis to trans isomerization is facilitated by high temperature, low pH, or visible light (213).  
Resveratrol has a low biological availability however, as only ~20% of available resveratrol in 
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the intestines of rats is absorbed (213).  Resveratrol has been shown to have anti-inflammatory 
properties, and its cardioprotective qualities have been implicated in the ‘French paradox’, the 
observation that French people suffer from a relatively low incidence of coronary heart disease 
despite a diet high in saturated fats (86; 102; 122; 196).  It has also been shown to have 
anticancer properties, due mainly to its cell cycle control and by initiating apoptosis in 
transformed cells (75).  Lastly, it has been shown to be beneficial to reduce oxidative stress in 
skeletal muscle as well (122; 123; 206).  
 Metabolic benefits.  Resveratrol appears to impart improvements in skeletal muscle 
metabolism.  It improved the health and survival of animals placed on a high fat diet, and 
protected them from metabolic disease (16; 139).  In a 2006 study by Lagouge et al., resveratrol 
treated mice placed on a high fat diet gained significantly less weight than non-treated mice 
placed on the same high fat diet, and also had much lower body fat percentages than the non-
treated animals (139).  The resveratrol treated mice had body weights and body fat percentages 
similar to a control group of standard chow diet mice.  These beneficial effects may have been 
due to the observed increases in basal energy expenditure and thermogenesis of the resveratrol 
treated mice in the study (139).   In a similar study by Baur et al., and using a lower dose of 
resveratrol than the Lagouge study, resveratrol supplementation did not significantly improve 
body weights of the treated animals (16).   However, in both the Baur and Lagouge studies, 
resveratrol treated mice were protected from insulin resistance, which had lower circulating 
levels of insulin and improved glucose tolerance compared to the non-treated mice put on a 
high fat diet (16; 139).  Subsequent studies have further suggested that resveratrol 
supplementation may stimulate glucose uptake in skeletal muscle independent of insulin, as 
well as increasing insulin-dependent glucose transport (54; 77; 186).  Furthermore, resveratrol 
has been shown to improve glucose tolerance in diabetic rats (54; 226).  These findings are 
noteworthy, as it is well known that muscle regeneration is impaired in certain metabolic 
disorders such as diabetes (112). 
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  Previous findings.  Recent work from our lab has also supported the role of resveratrol 
in reducing oxidative stress.  In a 2010 study by Ryan et al., resveratrol administration 
significantly lowered levels of oxidative stress in aged mice (206).  In this study, mice were 
pretreated with a 0.05% trans-resveratrol chow diet for ten days.  At day seven they were 
subjected to twenty maximal electrically-evoked isometric contractions.  This was repeated once 
more each of the next two days, whereupon the animals were sacrificed.  The results of this 
experiment showed that resveratrol supplementation attenuated the exercise-induced increase 
in xanthine oxidase activity, lowered hydrogen peroxide (H2O2) levels, and increased the ratio of 
reduced glutathione to oxidized glutathione in exercised muscles (206).  Furthermore, 
resveratrol increased the levels of both catalase and MnSOD in the exercised muscles. 
 In another 2010 study from our lab, Jackson et al. studied the effects of resveratrol on 
hindlimb suspended rats (123).  These animals were pretreated for 7 days with rat chow 
containing 0.05% trans-resveratrol, which corresponded to a dose of 12.5 mg/kg/day.  Following 
the pretreatment phase, the animals were suspended for a period of fourteen days.  Resveratrol 
was able to attenuate the disuse-induced decrease in plantar flexor isometric force in the aged 
animals, and also increased catalase activity, MnSOD activity, and MnSOD protein content in 
the gastrocnemius muscles of these animals.  It was also able to decrease H2O2 and lipid 
peroxidation levels in the muscles of the old animals.  This is important, as it has been 
suggested that reduced levels of oxidative stress are associated with faster muscle regenerative 
capabilities (259).  In a subsequent study by Jackson et al., it was demonstrated that long-term 
(10 month) resveratrol supplementation increases MnSOD and reduces both H2O2 and lipid 
peroxidation levels in aged mice (122).  It is interesting to note that while resveratrol was able to 
modulate oxidative stress levels in the study, it was unable to attenuate sarcopenia in the aged 
mice.  It is possible that the potential muscle-sparing benefits of resveratrol were not observed 
due to a lack of any significant muscle perturbation in these mice.  Ex vitro physiological 
analyses revealed no significant differences in muscle twitch properties, twitch/tetanus ratio, and 
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a fatigue index protocol in the resveratrol treated mice compared to the non-treated mice (122).  
However, resveratrol produced a rightward shift in a force frequency curve, which is suggestive 
of a preservation of the fast muscle phenotype with suspension.  It is currently unknown if this 
fast muscle preservation will translate into an improved muscle regenerative capacity.   
 Resveratrol and muscle atrophy.  In vitro, resveratrol has been shown to inhibit protein 
degradation and attenuate atrophy of skeletal muscle fibers in several studies (205; 254; 255).  
In vivo, these actions are not as well studied.  However, a recent study by Momken et al. 
examined some of the effects of resveratrol on skeletal muscle atrophy and function following a 
period of hindlimb suspension (171).  In this study, soleus muscle atrophy was significantly 
attenuated with resveratrol supplementation.  Also, resveratrol was able to ease the losses in 
type I fiber area following suspension.  However, resveratrol was not able to ameliorate maximal 
tetanic force (P0) losses observed following the suspension period.  Presently, there are no 
studies that examine the role of resveratrol in skeletal muscle regeneration. 
 Sirt1 in skeletal muscle.  While resveratrol has been shown to produce beneficial 
effects in a variety of studies, it is thought that much of this is due to its ability to activate Sirt1.  
Sirt1, the mammalian ortholog of yeast Sir2, was initially implicated as an important regulator of 
life span in this organism (130; 236), and subsequently in higher eukaryotes (154).  Sirt1 
belongs to the family of sirtuins (Sirt1-7), the class III protein deacetylases which use NAD+ as a 
cofactor in which their activity is regulated by NAD+/NADH ratios that change with respiratory 
activity (185).  Sirt1 may be activated in vivo through the aforementioned resveratrol 
supplementation protocol, a controlled regimen of caloric restriction (58), and with exercise 
(136).  However, recent evidence has suggested that Sirt1 is not directly activated through 
resveratrol (18; 184), but instead functions indirectly through the actions of AMP-activated 
protein kinase (AMPK) (41; 105).  Nevertheless, Sirt1 plays a varied physiologic role, regulating 
the activity of transcription factors and co-regulators which are involved in cell growth, 
metabolism, differentiation, survival, apoptosis, and the inflammatory or stress response (185).  
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While Sirt1 has been shown to play a protective role in age-associated pathologies such as 
diabetes, cancer, neurodegenerative disorders, and cardiovascular disease (108), its role in 
skeletal muscle regeneration and aging remains to be established. 
 PGC-1 activation.  The beneficial effects of Sirt1 on skeletal muscle metabolism are 
mainly due to its ability to deacetylate and activate the PPAR gamma coactivator 1, PGC-1 
(185).  Expression of PGC-1α in myotubes increases the expression of genes in the respiratory 
chain and enhances mitochondrial biogenesis by increasing the activity of the nuclear 
respiratory factor NRF1 and its target, mtfA, which in turn activates mitochondrial DNA 
replication (253).  PGC-1α is very important in oxidative metabolism, and the expression levels 
of both PGC-1α and Sirt1 are higher in the slower type I oxidative fibers as compared to the fast 
type II glycolytic fibers (151).  Under conditions of starvation, PGC-1α is responsible for inducing 
the switch in mitochondrial metabolism from glucose to fatty acid oxidation (92).  In vitro, Sirt1 
has been shown to deacetylate PGC-1α (179), and is required for the fasting induced 
deacetylation of PGC-1α in skeletal muscle (92).  As AMPK may be an upstream regulator of 
Sirt1 (41; 105), its inhibition prevents the deacetylation of PGC-1α by Sirt1 in response to 
glucose deprivation and exercise, therefore blocking the subsequent switch to fatty acid 
metabolism (41; 42). 
 Sirt1 appears to play a complicated role in skeletal muscle regeneration that is not yet 
fully understood.  It has been suggested that Sirt1 may alter the lineage/cell fate decisions of 
stem cells by sensing redox status (157; 161).  In a 2003 study by Fulco et al., in vitro analysis 
revealed that Sirt1 overexpression repressed the muscle transcriptional factor MyoD (89).  This 
in turn blocked several transcripts, including those encoding myogenin, thereby inhibiting the 
fusion of myoblasts into myotubes.  However, reducing Sirt1 levels by RNA interference resulted 
in the differentiation of myoblasts in these cultures (89).  The mechanism responsible for the 
inhibition of myogenesis is attributed to the recruitment of Sirt1 to muscle regulatory regions on 
chromatin through its interaction with a MyoD/PCAF complex and the histone acetyltransferase 
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GCN5, controlling the myogenic factor MEF2, and ultimately repressing the myogenic gene 
program (185).  Moreover, the NAD+ to NADH ratio and the redox state are closely linked to 
nutrient availability in muscle cells (242).  In a 2008 follow-up study by Fulco et al., cultured 
myoblasts exposed to glucose restriction showed enhanced Sirt1 activity through an AMPK-
dependent regulation of Nicotinamide monophorybosiltransferase (NAMPT), thereby preventing 
their differentiation into myotubes (88).  
 Sirt1 and insulin-like growth factor 1 (IGF-1) share downstream signaling targets in 
skeletal muscle, such as forkhead box-O transcription factors (FOXOs)(242).  Locally acting 
IGF-1 has been shown in numerous studies to impart great regenerative potential in both injured 
skeletal and cardiac muscle tissues (14; 175; 189; 210).  However, it has been shown that 
circulating IGF-1 levels counteract Sirt1 activity (58).  Likewise, levels of circulating IGF-1 were 
reduced during a regimen of caloric restriction (115).  Therefore, it appears that Sirt1 and 
circulating IGF-1 play opposing roles in longevity (153). 
 Does Sirt1 have a role to play in muscle regeneration?  While many beneficial 
effects have been observed with Sirt1, either directly or through its activation via resveratrol 
supplementation and/or caloric restriction, little is known about its role in skeletal muscle 
regeneration.  It remains to be established whether increased Sirt1 activity will improve satellite 
cell activation and function, thereby aiding muscle regeneration following injury or disuse.  
Therefore, the purpose of this study is to elucidate the role of Sirt1 in skeletal muscle 
regeneration through its actions on satellite cells.  We postulate that increasing the activity of 
Sirt1 in skeletal muscle will enhance regeneration following disuse or injury, due to enhanced 
satellite cell functioning, reduced mitochondrial-associated apoptosis, and a preservation of 
muscle mass and function following a period of disuse.  We will use both nutritional and genetic 
approaches in combination with models of disuse and injury to accomplish our aims.  
Establishing the efficacy of Sirt1 in the regeneration of skeletal muscle may hold implications for 
22 
 











Effects of resveratrol on disuse associated loss and hindlimb 
reloading in the plantaris muscle of aged rats 
 




Laboratory of Muscle Biology and Sarcopenia, Division of Exercise Physiology, West Virginia 






Introduction:  Aging is associated with an impaired skeletal muscle regenerative ability 
following perturbations such as extended periods of hospitalization and other forms of muscular 
disuse.  This may be due in part to a decrease in the total number and function of satellite cells, 
which are a major source of skeletal myoblasts which repopulate damaged and growing post-
natal skeletal muscle tissues.  Resveratrol (3,5,4’-trihydroxystilbene) is a naturally occurring 
phytoalexin which has been shown in skeletal muscle to improve oxidative stress levels and 
provide protection against disuse-induced muscle atrophy.  Therefore, we hypothesized that 
resveratrol supplementation would significantly improve muscle regeneration during a reloading 
period immediately following disuse. 
 
Methods:  For this study, a total of thirty-six male Fisher 344 × Brown Norway rats (32 mos.) 
were treated with either a water vehicle or resveratrol via oral gavage.  Animals underwent 
hindlimb suspension (HS) for a period of fourteen days, whereupon they were either sacrificed 
or allowed an additional fourteen day period of normal ambulation, the reloading period (R).  A 
total of six rats from each the vehicle and resveratrol treated groups were used for the HS and R 
protocols.  Furthermore, two groups of six vehicle treated animals maintained normal 
ambulation throughout the experiment, and were used as control animals for the HS and R 
groups.  The extent of satellite cell involvement in the regeneration of the plantaris muscles of 
the R animals was then examined to determine if the resveratrol treatment would prove 
beneficial.   
 
Results:  HS elicited decreases in both body and muscle weights of all of the animals.  
However, resveratrol supplementation was unable to attenuate these decreases.  Resveratrol 
was able to attenuate decreases in type IIA MyHC fiber CSA following HS, and type IIA and IIB 
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fibers following R.  Although resveratrol had no effect on the proportion of type I MyHC fibers 
following either HS or R, it significantly increased the proportion of type IIA fibers following HS.  
Lastly, although resveratrol could not protect the muscles from increased apoptosis as 
evidenced by TUNEL staining, it was able to alter apoptotic signaling as shown by an increase 
in anti-apoptotic Bcl-xL protein abundance following HS. 
 
Discussion:  Resveratrol supplementation has previously been shown to be beneficial to 
soleus muscles undergoing periods of disuse.  However, it is unknown if resveratrol can 
improve muscle recovery following this period of disuse.  Utilizing a relatively low dose (125 
mg/kg) of resveratrol, we observed benefits to muscle fiber CSA, fiber type distribution, and 
apoptotic signaling in our aging model of muscle recovery following disuse.  It is possible that a 
higher dose of resveratrol may be able to maximize these benefits.  Therefore, further research 
into this area should be undertaken in order fully elucidate the efficacy of resveratrol in 










 Skeletal muscle comprises 40-50% of the total mass in an average young adult human 
and is crucial for locomotion, metabolism, generating heat, and the maintenance of posture (24; 
131).  However, the natural process of aging induces an involuntary loss in muscle mass and 
function, due to the multifactorial condition commonly referred to as sarcopenia (36; 68; 246).  It 
is thought that as much as 50% of the population over the age of 80 suffers from this condition 
(15).  Sarcopenia has been shown to be predictive of falls (46), possibly leading to extended 
hospital stays and periods of immobilization.  This is noteworthy, as aging muscles display an 
impaired recovery following immobilization-induced muscle atrophy (47; 158; 227) 26).  One 
prominent factor which may prime this impaired recovery is the decline in satellite cell function 
observed with advancing age (44; 50; 61).   
 First described by Alexander Mauro in 1961, the satellite cell resides on the periphery of 
skeletal muscle fibers between the sarcolemma and basal lamina (163).  Normally quiescent, 
these cells are a major source of skeletal myoblasts which repopulate damaged and growing 
post-natal tissue while also having the ability to form new myofibers (17; 59; 211).  In response 
to sufficient perturbations in muscle homeostasis (e.g., muscle injury), satellite cells are 
activated, proliferate, and differentiate before committing to a myogenic lineage and repairing 
the tissue.  However, aging appears to induce functional limitations in this essential cell 
population.  Several studies have suggested that there is a delayed response to activation cues 
in aged muscles and their proliferative expansion is initially impaired as well (12; 27; 61; 214).  
Moreover, in vitro studies have shown an impaired differentiation capacity in aged satellite cells 
(50; 60).  It thus appears likely that the culmination of these defects lead to the reduced 
regenerative faculties in the elderly, reducing both the quality of life and functional 
independence of this population.  Therefore, developing therapies to counteract the inadequate 
satellite cell response to skeletal muscle insults in the aging population is of utmost importance. 
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 Resveratrol (3,5,4’-trihydroxystilbene) is a naturally occurring phytoalexin most notably 
found in the skin of red grapes (10; 116).  Thought to exert its effects primarily through the 
activation of the class III protein deacetylase Sirtuin 1 (Sirt1), resveratrol has been shown to 
benefit oxidative stress levels and also has anti-inflammatory, anti-cancer, and cardioprotective 
properties (75; 102; 122; 123; 196; 206).  Resveratrol has been shown to inhibit protein 
degradation and attenuate atrophy of skeletal muscle fibers in several in vitro studies (205; 254; 
255).  In vivo, the effects of resveratrol on skeletal muscle atrophy and growth are not well 
established.   A recent study by Momken et al. (172) examined several effects of resveratrol on 
skeletal muscle during a period of unloading in rats.  Using a relatively high dose (400 
mg/kg/day) of resveratrol, whole body net protein synthesis was maintained following hindlimb 
suspension, and resveratrol also attenuated soleus muscle atrophy and cross-sectional area 
(CSA) decreases following suspension.  This high dose of resveratrol also maintained tetanic 
force and twitch tension (172), demonstrating its potential to preserve muscle function following 
periods of disuse.  These beneficial effects of resveratrol on muscle force have also been 
observed in several other studies (80; 122; 139; 212).  Moreover, a recent study determined that 
resveratrol supplementation in vitro could inhibit dexamethasone-induced increases in the 
expression of the atrophy-related MuRF1 and atrogen-1 ligases, as well as attenuating 
increases in protein degradation (3).   
 While these and a multitude of other studies have examined the effects of resveratrol on 
various physiological measures in skeletal muscle, no studies to date have directly explored the 
relationship between resveratrol supplementation and muscle regeneration in aged animals.  It 
seems plausible, given the multiple benefits of resveratrol observed in skeletal muscle, that it 
may also improve muscle recovery following a period of disuse.  We therefore hypothesized that 
resveratrol supplementation would improve skeletal muscle regeneration/recovery (i.e. muscle 
mass and/or function) during a period of reloading immediately following disuse.  Such an 
observation is important because muscles from aged animals recover very little mass or 
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function after disuse (26). Our data showed that low dose resveratrol has little benefit during the 
unloading period, but it has some utility for improving muscle recovery after disuse in old rats. 
The findings of our study may potentially be applied to the development of novel therapeutic 
treatments to improve muscle recovery in individuals subjected to extended periods of disuse, 







Animals.  For this study, thirty-six male Fisher 344 × Brown Norway rats were obtained from the 
National Institute on Aging (NIA) colony that is housed at Harlan (Indianapolis, IN).  All of these 
animals were approximately 32 months of age.  The animals were housed at 20˚C in barrier-
controlled conditions under a 12:12 hour light-dark cycle.   Proper animal care standards were 
followed by adhering to the recommendations for the care of laboratory animals as advocated 
by the American Association for Accreditation of Laboratory Animal Care and by following the 
policies and procedures detailed in the Guide for the Care and Use of Laboratory Animals as 
published by the U.S. Department of Health and Human Services and proclaimed in the Animal 
Welfare Act (PL89-544, PL91-979, and PL94-279).  All experimental procedures carried 
approval by the Institutional Animal Care and Use Committee from the West Virginia University. 
 
Hindlimb suspension.  The animals were randomly assigned to either ambulatory cage control 
(CC; n=12), hindlimb suspended (HS; n=12), or reloaded (R; n=12) groups.  The hindlimb 
suspension lasted fourteen days as previously described (194).  Briefly, orthopedic tape was 
applied along the proximal one-third of the animals’ tail and then placed through a wire harness 
attached to a fish swivel.  This was fixed to the top of a specially designed hindlimb suspension 
cage which provided the rats with 360° of movement around the cage. The forelimbs maintained 
contact with a grid pattern floor, allowing the animals to move, groom themselves, and obtain 
food and water freely.  The exposed tip of the tail was closely monitored to ensure that it 
remained pink, indicating that HS did not interfere with blood flow to the tail. The suspension 
height was monitored daily and adjusted to prevent contact between the hind limbs and any 
supportive surface of the cage. Care was taken so that the suspension angle of the torso of the 
animals to the cage floor did not exceed 30°.  All animals were weighed prior to and following 
the suspension period to determine total body mass changes.  Furthermore, the R animals were 
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released from suspension after the fourteen day protocol and provided an additional fourteen 
days of normal ambulation, at which point they were weighed and sacrificed.   
 
Nutritional treatment.  Beginning one week prior to suspension, eighteen of the rats received 
1ml of 0.1% Carboxymethylcellulose dissolved in distilled water (vehicle treated), and the 
remaining eighteen rats received 1ml of trans-resveratrol suspended in 0.1% 
Carboxymethylcellulose dissolved in distilled water (resveratrol treated), administered via oral 
gavage.  Previous studies in our lab (122; 123) using resveratrol (12.5 mg/kg/day in the diet or 
50 mg/kg/day by oral gavage) were too low to effectively preserve muscle mass.  Therefore, in 
this study resveratrol was administered at a dose of 125 mg/kg/day in this study in order to 
increase the likelihood of detecting the effects of this compound on muscle wasting and 
regeneration. This provided a bolus increase in resveratrol every 24 hours.  Additionally, the 
resveratrol treated animals received an identical diet to the vehicle treated animals, but their 
chow also contained 0.05% resveratrol.  This provided a mechanism to provide a more 
consistently high level of resveratrol throughout the day.  Food and water was provided ad 
libitum. 
 
Bromodeoxyuridine administration.  Immediately following suspension, each of the R 
animals received a 200mg Bromodeoxyuridine (BrdU; 5-bromo-2’-deoxyuridine) pellet (21-day 
release; Innovative Research; Sarasota, FL) in order to analyze cell proliferation, as BrdU is a 
thymidine analog which is incorporated into nuclei during DNA synthesis.  Upon release from 
suspension, a small incision was made in the upper back of anesthetized animals whereupon 
the BrdU pellet was inserted subcutaneously.  The incision was closed with a wound clip 
(MikRon Autoclip 9mm; Becton Dickinson; Sparks, MD) and the animals were allowed to 




Research design.  Muscle data was obtained from both the resveratrol and vehicle-treated 
animals. In addition, two groups of ambulatory non-suspended cage control (CC) animals were 
used. Six CC animals were examined 21 days after the initiation of the study. These animals 
acted as controls for the HS groups.  A second group of six CC animals were examined 35 days 
after the initiation of the study and were used as controls for the R groups.  Among the 
suspended animals, six per diet group (i.e., vehicle or resveratrol) were sacrificed 21 days after 
the initiation of the study (HS) and another six animals per diet group were sacrificed 35 days 
after the initiation of the study (R).  The six HS CC and six R CC animals were also sacrificed at 
these respective time points. 
 
Animal sacrifices and tissue collection.  At the end of the 21 and 35 day experimental 
periods for the HS and R groups respectively, the animals were sacrificed while under deep 
anesthesia (5% Isofluorane/95% Oxygen).  The soleus, gastrocnemius, and plantaris muscles 
were excised from both hind limbs, blotted to remove excess fluid, and individually weighed.  
The weight of each muscle was normalized to the animals’ body weight and subsequently 
compared to determine if resveratrol preserved muscle mass.  A block obtained from the mid-
belly of the muscle was embedded in optimal cutting temperature (OCT) compound, flash frozen 
in liquid nitrogen cooled isopentane, and stored at -80°C until later analyses.  Once the muscle 
groups had been removed, blood samples were obtained from the left ventricle of each animal 
via a stainless steel needle (19G1½; Becton Dickinson; Rutherford, NJ).  The plasma was then 
measured (Protea Biosciences Group, Inc.; Morgantown, WV) to determine the concentration of 
resveratrol in each of the animals. Following blood collection, the animals were immediately 
euthanized by removing the heart with surgical scissors.  
 
Sirt1 activity.  Sirt1 activity was measured using components of the Sirt1 Fluorometric Drug 
Discovery Kit (BML-AK555; Enzo Life Sciences Inc.; Farmingdale, NY).  Briefly, endogenous 
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Sirt activity was measured in total plantaris muscle homogenates using the fluorescent 
deacetylase substrate and developer provided in the kit.  Muscles were homogenized in ice-cold 
distilled water and the protein concentrations were determined using a DC protein concentration 
assay (BioRad).  Samples were then diluted to 2.5 μg/μL using the reagents supplied in the kit.  
The fluorescent substrate, in conjunction with 100 μM of the cosubstrate NAD+, was then 
incubated with 15 μL of each sample for 45 minutes at room temperature (RT) in a ½ volume 
96-well white microplate.  Once complete, 2mM Nicotinamide (a Sirt1 inhibitor) and the provided 
fluorescent developer were added to each well to halt the reaction and produce a fluorophore 
which is linearly related to Sirt1 activity.  The intensity of the fluorescent signal was detected 
with an excitation wavelength of 360 nm and an emission wavelength of 460 nm.  Data is 
presented as fluorescent units normalized to the respective milligrams of protein used in each 
homogenate. 
 
Ex vitro muscle physiological analyses.  Isometric muscle contractile properties were 
examined in the plantaris muscles from the left leg of all experimental animals. The muscles 
were placed in an oxygenated Ringer’s solution (137 mM NaCl, 4.7 mM KCl, 3.4mM CaCl2, 
1.2mM MgSO4, 1 NaH2PO4, and 112 D-glucose), which was maintained at 20°C. The Ringer’s 
solution was aerated with 95% O2 and 5% CO (pH 7.4). The distal end of the muscle was 
attached to a stationary plexiglass plate, and the proximal end fixed to the lever arm of a 300C 
dynamometer (Aurora Scientific, Aurora Ontario, Canada).  The muscles were stimulated by 
passing a constant current through platinum plates positioned on each side of the muscle.   Ex 
vitro isometric twitch and tetanic contractions were obtained using a Constant Current/Constant 
Voltage Stimulator (Aurora Scientific) that provided DC-square wave signals at a stimulation 
current of 12 Volts, with a 200 µs pulse width.  Muscles were adjusted to the optimal muscle 
length (Lo) by a micromanipulator that controls the base position of the electrode clamp.  Lo was 
established as the muscle length that produced maximal isometric twitch tension and was 
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periodically checked by the same procedure throughout each experiment to maintain this length.  
Force-frequency isometric force records were obtained by stimulating the muscle at 10, 20, 40, 
50, 75 and 100 Hz, with 3 minutes of rest between each contraction.  Physiological contractile 
measures included peak isometric twitch force (PT), time to peak twitch contraction tension 
(CT), and the ½ relaxation time of twitch contraction (½ RT), as previously described (7).  
Following isometric contractions, the muscles remained in the oxygenated Ringer’s solution for 
5 minutes prior to the repeated stimulation fatigue protocol. Muscle fatigue was assessed by 
stimulating the muscle at 40Hz for 3 minutes utilizing a duty cycle of 330 ms of stimulation 
followed by 660 ms of rest (53).  The fatigue index was calculated as the force from the last 
contraction expressed as a percentage of the force obtained on the first contraction.  The 
contractile and fatigue measurements were analyzed off line using commercial software (DMI, 
Aurora Scientific). 
 
Fiber characteristics.  Muscle fiber type and cross-sectional area (CSA) analyses were 
performed in the plantaris muscles.  Frozen tissue cross sections measuring 10-μm thick were 
cut from the mid-belly of the muscles, mounted on charged microscope slides (Fisher Scientific; 
Pittsburgh, PA), and stored at -80°C.  For analysis, the slides were air-dried 30 minutes, washed 
in PBS, and incubated for 30 minutes at RT with 4% bovine serum albumin (BSA) in PBS.  The 
tissue sections were incubated overnight at 4°C with antibodies directed against laminin 
(MAB1914; Millipore; Temecula, CA) to visualize the basal lamina of each muscle fiber, as well 
as one of the following individual myosin heavy chain (MyHC) antibodies: BA-D5 (for MyHC I; 
Developmental Studies Hybridoma Bank; Iowa City, IA), SC-71 (for MyHC IIA; DSHB), and BF-
F3 (for MyHC IIB; DSHB) in order to determine both the whole muscle composition and mean 
cross-sectional area (CSA) for each respective fiber type.  Next day, the slides were washed in 
PBS and incubated 1 hour at 37°C with secondary antibodies of donkey anti-rat rhodamine 
(712-025-150; Jackson ImmunoResearch Laboratories; West Grove, PA) to visualize the basal 
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lamina, and Alexa Fluor 488 (A10680; Invitrogen; Eugene, OR) to visualize the MyHC fibers.  
The sections were mounted with 4', 6-diamidino-2-phenylindole (DAPI) (Vectashield Mounting 
Medium; Vector Laboratories; Burlingame, CA) to visualize the nuclei.  Four images from non-
overlapping regions of each tissue cross-section stained for individual MyHC fibers were used 
for both fiber type proportions and respective CSA’s.  All images were taken with a Zeiss LSM 
510 Meta confocal microscope (Carl Zeiss Microimaging Inc.; Thornwood, NY) at a 
magnification of 20X.  Mean fiber CSA of respective fiber types was determined by planimetry 
and calculated by the ImageJ software (NIH; Frederick, MD).   Fiber types are expressed as a 
proportion of MyHC-positive fibers to total fibers for each individual MyHC examined.  The 
percentage of type IIX MyHC fibers was calculated as the remainder once the type I, IIA, and IIB 
MyHC fiber percentages had been subtracted from one-hundred percent.  
 
Western blotting.  Western blots were used to determine the relative amount of proteins in 
apoptotic signaling pathways following HS and R.  Approximately seventy-five micrograms of 
muscle was homogenized in ice-cold modified RIPA buffer (50mM Tris, 1% NP-40, 150mM 
NaCl, 1mM EDTA, 0.1% SDS, 0.5% Na-deoxycholate; pH: 7.4) containing protease and 
phosphatase inhibitors. The muscle homogenates were centrifuged at 1,000g for 5 minutes at 
4°C, and the resulting supernatant was collected.  The protein content of the samples was 
measured using the DC protein assay kit (BioRad; Hercules, CA). Thirty-five micrograms of 
protein was loaded into each well of a 4-12% gradient polyacrylamide gel (Invitrogen; Carlsbad, 
CA) and separated by routine sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) for 2 hours at 135V. The proteins were then transferred to a nitrocellulose membrane for 
2 hours at 35V.  Non-specific protein binding was blocked by incubating the membranes in 5% 
nonfat milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) at RT for 1 hour. 
Membranes were incubated overnight at 4°C on a rocking table with primary antibodies 
(1:1,000) directed against Bcl-xL (#2762; Cell Signaling Technology; Boston, MA) and Bax 
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(#2772; Cell Signaling).  Furthermore, a primary antibody (1:2,000) was directed against 
GAPDH (ab8245; Abcam; Cambridge, MA) for use as a loading control.  The following day, the 
membranes were washed in TBST and incubated in appropriate dilutions of secondary 
antibodies (diluted in 5% non-fat milk) conjugated to horseradish peroxidase for one hour at RT 
on a rocking table. The signals were developed using a chemiluminescent substrate (Lumigen; 
Southfield, MI) and visualized by exposing the membranes to x-ray film (BioMax MS-1; Eastman 
Kodak, Rochester, NY).  Digital records of the bands were captured using a Kodak 290 camera 
and quantified using one-dimensional analysis software (Eastman Kodak) as optical density × 
band area, expressed in arbitrary units relative to appropriate loading controls.  
 
Identification of apoptotic nuclei.  Frozen tissue 10-μm thick cross sections were obtained 
from the plantaris muscles and mounted on charged microscope slides (Fisher Scientific; 
Pittsburgh, PA).  Fluorescent labeling of terminal dUTP nick-end labeling (TUNEL) with lamina 
allowed the detection of apoptotic nuclei in the muscle sections. This was accomplished using a 
slight modification to the method previously reported for our lab (219).  Briefly, the tissue 
sections were air dried, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-
100 in PBS for 30 minutes each at room temperature. The tissues were incubated overnight at 
4°C in a rat anti-lamina monoclonal antibody (Millipore). Sections were incubated the following 
day with donkey anti-rat rhodamine conjugated secondary antibody (Jackson 
ImmunoResearch), along with the TUNEL reaction mixture (11-684-795-910; Roche 
Diagnostics; Indianapolis, IN) in a humidified chamber at 37°C for 1 hour in the dark. The 
exclusion of the TdT enzyme in the TUNEL reaction mixture on one of the tissue sections on 
each slide was included as a negative control. The sections were mounted with DAPI 
(Vectashield) in order to visualize nuclei and viewed under a Zeiss LSM 510 Meta confocal 
microscope (Carl Zeiss Microimaging Inc.; Thornwood, NY).  The number of TUNEL and DAPI-
positive nuclei that were immediately adjacent to, or beneath the basal lamina were counted. 
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Data is expressed as an apoptotic index, calculated as the percentage of TUNEL-positive nuclei 
out of the total myonuclei (i.e., DAPI-positive nuclei) pool. The apoptotic index was determined 
from four non-overlapping regions of each tissue cross section visualized with a 20X objective.  
 
BrdU detection.  Frozen tissue cross sections measuring 10-μm thick from the plantaris muscle 
were mounted on charged microscope slides (Fisher Scientific; Pittsburgh, PA).  Briefly, tissue 
sections were air dried, washed in PBS, fixed in methanol:acetone (1:1) at -20°C for 5 minutes, 
and permeabilized with 0.4% Triton X-100 in PBS.  Sections were then denatured using 
Reagent 2 and blocked with Reagent 3, both components in the Calbiochem BrdU 
Immunohistochemistry System (HCS30; EMD Biosciences, Inc.; La Jolla, CA).  Sections were 
incubated overnight in a biotinylated mouse anti-BrdU primary antibody.  On the following day, 
sections were incubated with a secondary antibody of Fluorescein Avidin DCS (A-2011; Vector 
Laboratories, Inc.; Burlingame, CA) and subsequently blocked in normal goat serum.  They 
were then incubated overnight in a rat anti-lamina monoclonal (Millipore) primary antibody. 
Sections were incubated the following day with a donkey anti-rat rhodamine conjugated 
(Jackson ImmunoResearch) secondary antibody in a humidified chamber at 37°C for 1 hour in 
the dark.  Finally, the sections were mounted with DAPI-containing mounting medium 
(Vectashield) in order to visualize nuclei.  Immunofluorescence was visualized with a Zeiss LSM 
510 Meta confocal microscope (Carl Zeiss).  Images were taken from four non-overlapping 
regions of each tissue section with a 20X objective.   
 
Statistical analysis.  All results are reported as means ± SD.  Differences in means between 
groups were determined by multiple analysis of variance (MANOVA) Hotelling's T-Square test. 
Bonferroni post hoc analyses were subsequently performed between significant means. A p-






Body weight.  We measured the bodyweight of all animals at the beginning of the one-week 
pretreatment period (Start), immediately prior to suspension (Day 0), following suspension (HS), 
and following the recovery period (R).  There were no differences in bodyweight between any of 
the groups at the beginning of the experimental protocol.  Furthermore, no significant changes 
in bodyweight were observed in the cage control animals at any of the time points.  In the 
suspended animals, HS induced a significant loss of bodyweight in all of the animals as 
compared to the first day (Start) of the experiment, with decreases of 24.6% and 18.0% 
observed in the vehicle and resveratrol treated groups, respectively.  These significant losses 
continued into the R period as well, with vehicle and resveratrol treated animals losing an 
additional 3.7% and 5.6% of body mass, respectively, between the end of HS and the end of the 
R period.  However, resveratrol was unable to attenuate any of these bodyweight reductions, as 
there were no significant differences observed between the vehicle and resveratrol treated 
animals at any of the individual time points of the study (Figure 1A). 
 
Muscle wet weight.  Upon sacrifice, the plantaris muscle wet weights were examined to assess 
changes in muscle mass following the suspension and recovery periods.  It was determined that 
HS induced significant decreases (P<.001) in absolute muscle mass in both the vehicle and 
resveratrol treated groups as compared to the HS control animals (Figure 1B).  However, there 
were no differences observed between the vehicle and resveratrol treated animals.  Following 
the R period, the wet weights from both the vehicle and resveratrol treated animals fully 
recovered to that of the control animals’ muscle mass.  Moreover, there were no significant 




Muscle contractile characteristics.   Freshly isolated plantaris muscles were attached to a 
force transducer in order to determine various muscle contractile properties following HS and R.  
Following HS, there was a significant increase (P<.001) in CT during a twitch contraction in both 
the vehicle (78.6 ± 5.3 ms) and resveratrol (86.2 ± 10.6 ms) treated groups as compared to the 
cage controls (38.7 ± 6.8 ms).  However, resveratrol was unable to attenuate this increase 
(Figure 2A).  In the R group, the CT of both the vehicle (78.0 ± 6.4 ms) and resveratrol (86.2 ± 
10.6 ms) animals was significantly greater than that of the R Con (62.0 ± 8.0 ms) animals 
(Figure 2B).  There were no differences observed when comparing the CT of the vehicle and 
resveratrol treated animals.  
 Next, we examined the ½ RT during a twitch contraction.  In the HS group, the ½ RT 
was significantly shorter in the vehicle treated (47.4 ± 11.8 ms) animals compared to either the 
resveratrol (65.8 ± 7.8 ms) or cage control (69.8 ± 9.6 ms) groups (Figure 2A).  Moreover, there 
were no differences between the resveratrol and cage control groups at this time point.  This 
same trend also continued into the R period (Figure 2B).  While there were no differences in the 
½ RT between the resveratrol (71.3 ± 18.1 ms) and cage control (61.2 ± 13.0 ms) groups, the ½ 
RT of the vehicle treated (42.7 ± 3.8 ms) group was significantly shorter than both of these two 
groups.     
 A fatigue index (see “Materials and Methods”) was examined in order to determine if 
resveratrol had improved the muscles fatigue tolerance during a series of contractions.  As 
expected, HS elicited a significant decrease in the muscles resistance to fatigue.  Both the 
vehicle (11.3 ± 2.6%) and resveratrol (11.6 ± 2.9%) animals had significantly reduced fatigue 
indexes as compared to the cage control (16.6 ± 1.8%) group (Figure 2C).  However, there were 
no differences observed between the resveratrol and vehicle treated animals.  In the R animals, 
the vehicle treated animals had a similar fatigue index (10.9 ± 1.6%) as the resveratrol (9.5 ± 
1.8%) fed group; however the fatigue index of the resveratrol group was significantly lower than 
the cage control (14.8 ± 4.8%) group after reloading (Figure 2C).   
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 Lastly, we plotted the force-frequency curve for the HS and R groups.  In the HS 
animals, a frequency of 20 Hz produced a significant rightward shift in both the vehicle and 
resveratrol treated groups (Figure 2D).  At 50 Hz, there remained a significant rightward shift in 
the resveratrol animals curve compared to both the cage control and vehicle treated animals.  In 
contrast, there were no differences observed between the vehicle treated and cage control 
groups.  At 75 Hz, both the vehicle and resveratrol treated groups reached their peak relative 
forces, which shifted their curves significantly above that of the cage control group.  
Furthermore, the curve for the vehicle treated group was significantly higher than that for the 
resveratrol treated group. 
 In the R animals, both the vehicle and resveratrol treated groups’ force-frequency curves 
were significantly shifted to the right of the cage control curve at 10, 20, and 50 Hz (Figure 2E).  
However, at none of these frequencies did the curve of either the vehicle or resveratrol groups 
differ from each other.  While there remained no difference between the curves of the vehicle 
and resveratrol treated groups at 75 Hz, only the curve for the resveratrol animals maintained a 
significant rightward shift from that of the cage controls.  
 
Sirt1 activity.  Blood plasma analysis of the resveratrol treated animals revealed a resveratrol 
concentration ranging from 176 to 5430 ng/ml in the HS group and from 81 to 934 ng/ml in the R 
group.  There were no traces of resveratrol in the plasma of any of the vehicle treated animals.  
The relative activity of Sirt1 in the plantaris muscles of all of the animals was assessed using a 
fluorometric assay.  In the HS animals, there were no significant differences in Sirt1 activity 
between any of the groups, although there was a trend towards higher levels in the resveratrol 
treated animals (Figure 3).  This trend continued with the R groups as well, although the 
differences between the groups was less than it was in the HS animals. This was due to both 
the R control and vehicle treated animals Sirt1 activity levels being slightly increased from that 




 MyHC profile.  To determine if resveratrol had any effect on fiber composition following HS or 
R, we examined the myosin heavy chain (MyHC) profile of the plantaris muscles.  Following HS, 
the relative percentage of type I MyHC fibers was significantly reduced in both of the groups 
subjected to suspension.  However, there were no differences between the vehicle and 
resveratrol treated animals, although the mean percentage was slightly higher in the resveratrol 
group (Figure 4A).  For the type IIA MyHC fibers, the resveratrol treated animals had a greater 
percentage than either the vehicle treated or cage control animals, which showed no differences 
between the two.  Suspension significantly increased the percentage of type IIB fibers, although 
resveratrol had no effect on the composition of this fiber type compared to the vehicle treatment.  
In contrast, the percentage of type IIX MyHC fibers was significantly reduced after suspension in 
the resveratrol treated animals from that of the control muscles.  However, there were no 
significant differences between the two suspended groups. 
 In the R animals, the percentage of type I fibers remained significantly diminished in the 
animals that had previously been suspended.  However, there was an increase in this fiber type 
in the vehicle treated animals to where the resveratrol treated animals no longer had a greater 
proportion of this fiber type (Figure 4B).   While the percentage of type IIB fibers remained 
significantly elevated in both the vehicle and resveratrol treated animals, there remained no 
differences between these two groups.  Lastly, although the resveratrol treated animals 
maintained a reduced percentage of type IIX MyHC fibers, the proportion of these fibers were 
also significantly reduced in the vehicle treated animals as well.   
 
Fiber size.  Muscle fiber CSA measurements were determined by planimetry and were 
analyzed for each type I, IIA, and IIB MyHC fibers.  In the HS animals, the suspension induced 
significant muscle atrophy in all of the fiber types examined.  In type I fibers, no differences in 
mean fiber CSA measurements were noted between the vehicle and resveratrol treated 
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animals, although both had significantly smaller fibers than the cage control animals.  In type IIA 
fibers, only the vehicle treated animals had myofibers with mean CSA’s significantly smaller 
than that of the cage control animals (Figure 4C).  The mean CSA’s from the resveratrol treated 
animals were no different than the control animals, indicating that resveratrol partially preserved 
muscle fiber area during HS in this particular fiber type.  In the type IIB MyHC fibers, both the 
vehicle and resveratrol treated groups mean CSA measurements were significantly smaller than 
those of the cage control animals.  However, no significant differences were noted between the 
vehicle and resveratrol treated animal’s myofibers in this fiber type following HS.  
 In the R animals, the same relative pattern persisted as it did in the HS animals (Figure 
4D).  In type I MyHC fibers, the mean CSA remained significantly smaller in both the vehicle and 
resveratrol treated animals as compared to the cage controls.  In the type IIA fibers, only the 
vehicle treated animals had a significantly reduced mean CSA compared to the cage control 
animals.  While the mean CSA of the resveratrol treated animal’s fibers were not statistically 
different than the vehicle treated animals, the reduction in myofiber size from control levels 
appeared to be partially attenuated with resveratrol treatment, as these differences did not 
reach significance.  Moreover, although the mean type IIB fiber CSA remained significantly 
reduced in the vehicle treated animals, the mean CSA of the resveratrol treated animals 
somewhat recovered and was no longer statistically smaller than the control fibers.  
 
BrdU incorporation.  A BrdU pellet was implanted into all of the R animals.  As we were most 
interested in the regenerative period following HS, these animals received the pellet 
immediately upon being released from suspension.  BrdU-positive myonuclei were expressed 
per 100 myofibers.  BrdU incorporation was very limited in the cage control (0.34 ± 0.61) 
animals, as there was no stimulus to activate any available satellite cells from quiescence under 
these homeostatic conditions (Figure 5).  With the significant atrophy we observed in all of the 
animals subjected to suspension, it was not surprising that there was a significant increase in 
42 
 
BrdU incorporation in both the vehicle (7.80 ± 3.23) and resveratrol (11.00 ± 3.54) treated 
animals, as satellite cells were activated  upon reloading, presumably in an attempt to recover 
the muscle mass lost during HS.  However, there were no statistical differences observed in the 
incorporation of BrdU between the vehicle and resveratrol groups.     
 
Apoptotic signaling.  We have previously characterized apoptotic protein changes during 
hindlimb suspension and reloading (36). In this study, western blots were used to determine the 
relative levels of the anti-apoptotic Bcl-xL and pro-apoptotic Bax proteins as representative 
proteins in the apoptotic signaling pathway.  Protein levels were normalized to GAPDH protein 
levels and are expressed in arbitrary units.  In the HS group, there were no differences 
observed between any groups in Bax protein content (Figure 6A).  However, Bcl-xL protein 
levels were significantly increased in the resveratrol (0.49 ± 0.12) treated group following HS, 
while no changes were observed in the vehicle (0.20 ± 0.16) treated group as compared to the 
cage control (0.28 ± 0.11) animals (Figure 6B). 
 In the R group, there were once again no differences observed in Bax protein content 
between the vehicle (0.80 ± 0.34) and resveratrol (0.68 ± 0.35) treated animals, nor were these 
values different than those of the cage control (0.84 ± 0.32) animals (Figure 6A).  While the Bcl-
xL protein levels remained low in the cage control (0.25 ± 0.16) animals, these values increased 
significantly in both the vehicle (0.61 ± 0.15) and resveratrol (0.65 ± 0.14) treated animals, 
although there were no differences observed between these two groups (Figure 6B). 
 To complement the western blot analysis, we used a TUNEL assay in order to determine 
the relative amount of myonuclei undergoing apoptosis immediately following HS (Figure 6C, 
6E) and R (Figure 6D, 6E).  As expected (101), both HS groups experienced a significant 
increase in apoptosis following HS.  While insignificant, the mean increase in the apoptotic 
index was 29% higher in the vehicle (1.35 ± 0.49) treated animals compared to the resveratrol 
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(0.96 ± 0.50) treated animals.  In the R group, the TUNEL index remained significantly elevated 










 In this study we examined only aged animals, because we were interested in the effects 
of resveratrol on muscle atrophy and recovery following disuse in aged animals, and not in 
identifying differences in response between young and old animals. As expected (101; 117; 
256), a fourteen day period of suspension induced significant reductions in both body and 
muscle weights in the aged animals.  Although both the vehicle and resveratrol treated animals 
lost this body weight during the suspension period, resveratrol had no effect on the overall body 
mass changes.  This is in agreement with several other studies in which resveratrol had no 
effect on fluctuations in body mass following suspension (95; 123; 172).  Furthermore, this trend 
continued into the recovery period.  While the body masses of both the vehicle and resveratrol 
treated animals maintained a slight decline in body mass through this period, resveratrol did not 
have any measurable effect. 
 Following HS, the muscle wet weights of both the vehicle and resveratrol treated animals 
were significantly reduced.  However, resveratrol was unable to attenuate these losses in 
muscle mass.  Although a high dose (400 mg/kg) of resveratrol has been shown to protect 
soleus muscles from HS-induced atrophy (172), lower doses (12.5 mg/kg) have been shown to 
not have any effect on this atrophy in gastrocnemius muscles (123).  Thus it is likely that any 
protective effects of resveratrol against disuse atrophy are muscle and/or dose specific.  The 
latter appears to be the case for our current study, as in addition to the plantaris muscles, 
resveratrol was also unable to attenuate the HS-induced decreases in muscle mass in the 
soleus or gastrocnemius muscles (data not shown) of these animals.  Moreover, there was no 
improvement in muscle mass with resveratrol supplementation following the R period.  At this 
stage, both the vehicle and resveratrol animals which had been previously suspended had 
muscle weights that were not statistically different from that of the cage control animals, 
although the means of each were still slightly reduced.  Thus, our observations lead us to 
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speculate that our current dose of resveratrol was insufficient to maximize any potential benefits 
on muscle mass in this particular model.  Furthermore, as the masses from both the vehicle and 
resveratrol animals were fully restored following fourteen days of recovery, it is not known 
whether resveratrol supplementation is able to shorten this recovery. 
 We examined several contractile properties of the muscles from both the HS and R 
animals to determine if resveratrol had any effect on muscle function.  Upon examination of the 
muscle twitch properties, we observed a suspension-induced decrease in the ½ RT, as was 
expected (79; 172).  However, this decrease was completely ablated in both the HS and R 
groups that received the resveratrol supplementation.  This is in agreement with another recent 
study, which found resveratrol to be effective in preventing decreases in ½ RT following a period 
of disuse (172).  This could occur by several means including maintenance of SERCA proteins 
and improved calcium uptake at the sarcoplasmic reticulum, but this was not assessed in the 
current study.  We next examined the fatigue properties of the plantaris from animals in the HS 
and R groups.  The fatigue index revealed a decrease in the ability of the plantaris to withstand 
repeated contractions in both of the groups subjected to suspension.  Although there were no 
differences in the fatigue index of the vehicle and resveratrol treated animals following HS, it 
was determined that only the resveratrol treated animals had a fatigue index value which was 
significantly less than that of the control animals following the R period.  While it was 
unexpected that the resveratrol treated animals would have a reduced fatigue index, the 
observation that resveratrol treatment does not improve upon the index is not without precedent.  
In other studies involving resveratrol supplementation (80; 122), no improvements were 
observed in a fatigue index protocol.  However, it must also be noted that in one study in which 
young, dystrophic mdx mice were supplemented with resveratrol, there was a significant 
improvement of the observed fatigue index (212).  Given the contradicting results of these 
studies, it is only possible to state that the possible effects of resveratrol on skeletal muscle 
fatigue remain inconclusive, and very likely are conditional to the specific experimental models 
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used to observe these effects.  Therefore, further research in this area is needed to reconcile 
these discrepancies.  
 In examining the force-frequency curves of both the HS and R groups, we observed a 
rightward shift in both of the groups that had been subjected to suspension.  This shift was 
prominent at the lower frequencies in the HS groups and was further exacerbated in the R 
vehicle and resveratrol treated groups.  This rightward shift is suggestive of a faster muscle 
phenotype, which is consistent with our observations of the fiber type composition of these 
muscles.  While the proportion of type I MyHC fibers decreased in both the resveratrol and 
vehicle treated animals following suspension, there was a very significant increase in type IIB 
fibers.  Concomitantly, there was also a slight increase in type IIA MyHC fibers, although this 
only reached significance in the resveratrol treated HS animals and did not continue into the R 
period.  These results were slightly different than that reported in a recent study by Momken and 
colleagues (36).  Under similar experimental conditions as our present study, they observed that 
resveratrol supplementation attenuated the decrease in type I MyHC fibers following suspension 
(172).  They attributed this finding to the ability of resveratrol, acting primarily through Sirt1, to 
increase the expression of PGC-1α, which has been shown to promote the maintenance of 
slow-twitch fiber’s oxidative characteristics (99).  However, our current findings most likely differ 
from the Momken et al. findings due to the specific muscles examined in each study.  While our 
current study utilized the primarily glycolytic plantaris muscles, Momken et al. (36) examined the 
much more oxidative soleus muscles.  Nevertheless, the effects of resveratrol might be muscle 
specific because the type I fibers in the plantaris of resveratrol and vehicle treated animals had 
similar reductions in cross sectional area after HS or R. Thus, the protective effect on type I fiber 
composition observed reported by Momken and colleagues (36) did not appear to occur in our 
present study.  
 As is typical of muscles subjected to periods of unloading, we observed a decrease in 
the mean CSA of the plantaris muscles.  Although resveratrol supplementation did not have an 
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effect on type I fiber size following either HS or R, it did have an impact on type II fiber area.  
Following HS, resveratrol effectively attenuated the significant loss of type IIA fiber area.  
Furthermore, resveratrol benefitted the type II fibers following the R period, as both type IIA and 
IIB fiber areas were not different than control fibers, whereas the type II fibers of the vehicle 
treated animals remained significantly smaller than control muscle fibers during the R period.  It 
was not surprising that resveratrol benefitted muscle fiber size, given that similar results have 
been observed in several recent studies (3; 172).  These beneficial effects observed in our 
current study are most likely due to resveratrol being able to attenuate muscle protein 
degradation during conditions which normally would induce atrophy (3), and not due to an 
increased growth response per se during the period of recovery following our suspension-
induced atrophy protocol.  This is supported in part by our examination of BrdU-positive nuclei 
during this recovery period.  Analyzing the BrdU-positive nuclei (i.e., satellite cells) allowed us to 
observe the activation of these muscle precursor cells throughout the R period.  However, we 
did not observe any differences between the vehicle and resveratrol treated animals in this 
context, indicating that our current dose of resveratrol was insufficient at increasing the 
activation, and thereby muscle growth potential, of the latent satellite cells.  Thus, it is likely that 
the benefits of resveratrol in providing an increased muscle size recovery are due to its’ 
attenuating the suspension-induced atrophy throughout the HS period. 
 Recent work has shown resveratrol to have beneficial effects on apoptosis in multiple 
different tissues (4; 94; 123; 261).  Therefore, we examined representative indicators of positive 
and negative apoptotic signaling to determine if resveratrol was beneficial following HS and R in 
our specific model.  Although no changes were observed in Bax protein expression following 
either HS or R, Bcl-xL protein expression was significantly elevated in the resveratrol treated 
animals following HS. This is consistent with an attenuation of muscle fiber size during HS in 
resveratrol treated animals.   However, there were no differences in the abundance of these 
apoptotic proteins observed between the vehicle and resveratrol treated animals following R.  
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Likewise, in examining TUNEL-positive nuclei, we did not observe any significant differences 
between the vehicle and resveratrol treated animals following either HS or R, although the mean 
TUNEL index values were slightly lower in the resveratrol treated animals.  Thus it is likely that 
the beneficial, albeit minor, effects of resveratrol on Bcl-xL protein levels were sufficient to 
partially mediate decrements in myofiber size which were observed following the HS period in 
our current study. 
 The findings from our present study provide evidence for the modest benefits of 
resveratrol supplementation in improving skeletal muscle regeneration following a period of 
disuse with a subsequent recovery.  Although resveratrol did not preserve either body or muscle 
weight decrements following HS, it was able to induce favorable changes to type IIA and IIB 
muscle fiber CSA measurements and apoptotic signaling.  This is particularly relevant in the 
elderly population which experience preferential atrophy of type II fibers in sarcopenic 
conditions.  The potential caveat of this study may be that the dose of resveratrol used was 
simply not enough to elicit the full benefits of its regenerative capabilities on all fiber types.  
Thus, the evidence from this study warrants the further research into this subject, as resveratrol 
supplementation holds promise of a novel treatment to combat the decline of muscle function in 








Figure 1.  Body and muscle wet weights.  A)  Bodyweights measurements of all animals were 
taken immediately prior to the start of the one-week pretreatment period (Start), immediately 
prior to suspension (0), following the suspension period (HS), and again following the reloading 
period (R).  B)  Plantaris muscle wet weights were analyzed either following HS or R.  # P<.05 
vs. CC. 
 
Figure 2.  Plantaris muscle force characteristics.  A,B)  Muscle twitch properties including 
CT and ½ RT were analyzed in the plantaris muscles of both the HS (A) and R (B) groups.  C)  
A fatigue index was calculated from a series of 128 consecutive contractions.  D,E)  A force-
frequency curve was plotted for both the HS (D) and R (E) groups.  * P<.05 vehicle vs. 
resveratrol, # P<.05 vs. CC. 
 
Figure 3.  Sirt1 activity.  The relative activity of Sirt1 was determined in all of the animals.  
Values are in fluorescent units normalized to the respective milligrams of protein used in each 
sample.   
 
Figure 4.  Muscle fiber composition and morphology.  A,B)  Individual MyHC fiber 
composition was analyzed in both the HS (A) and R (B) groups to determine the relative 
composition of the plantaris muscles.  C,D)  Mean fiber area measurements were performed in 
type I, IIA, and IIB MyHC fibers in the HS (C) and R (D) groups.  E)  Representative images of 
fiber type staining (type I MyHC) for fiber type composition and CSA analyses for both the HS 
and R groups.  Green fibers are MyHC-positive.  Scale bars represent 50 µm.  * P<.05 vehicle 




Figure 5.  BrdU incorporation.  In order to analyze cellular proliferation during the reloading 
period, a BrdU pellet was inserted into the R animals as they were released from suspension.  
BrdU incorporation is expressed as the number of BrdU-positive myonuclei per one-hundred 
fibers.  # P<.05 vs. CC. 
 
Figure 6.  Apoptosis.  A,B) Western blots were utilized to determine the relative levels of pro-
apoptotic Bax (A) and anti-apoptotic Bcl-xL (B) proteins.  Units are expressed in arbitrary units 
relative to appropriate GAPDH protein levels.  C,D,E)  DNA fragmentation was assessed with 
TUNEL staining in both the HS (C,E) and R (D,E) groups.  Figures C and D are representative 
images taken from the HS and R groups, respectively.  * P<.05 vs. vehicle, # P<.05 vs. CC.     
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Silent mating type information regulator 2 homolog 1 (Sirt1), an NAD+-dependent histone 
deacetylase, has been implicated in the regulation of lifespan, tumorigenesis, aging, metabolism 
and gene expression.  Recent work has also begun to uncover a possible role for Sirt1 in the 
regulation of skeletal muscle mass and function.  We thereby utilized a cardiotoxin (CTX)-
induced muscle injury protocol to determine the effects of either the suppression or 
overexpression of Sirt1 on skeletal muscle regeneration in older-age (18-22 mo) transgenic 
animals.  The left tibialis anterior (TA) muscle of all the animals were injected with CTX, while 
the right TA was injected with an identical volume of PBS and used as an intranimal control.   
Animals were then allowed to recover for a period of 3 or 7 days before both TA muscles were 
surgically removed and the animal was sacrificed.  Sirt1 expression did not have an effect on 
muscle mass or fiber area in this model, which was not surprising considering it also did not 
alter satellite cell activity.  However, increasing Sirt1 expression increased maximal tetanic force 
production in the regenerating muscles as compared to respective WT muscles which may 
indicate improved functional recovery in these muscles.  Overall, these results suggest a slightly 
improved muscle recovery with increased Sirt1 expression.  Future research should be 
conducted to determine if clinically modulated Sirt1 expression levels will prove beneficial in 








 Silent mating type information regulator 2 homolog 1 (Sirt1) is a class III histone 
deacetylase (HDAC) which has been implicated in lifespan extension in several model 
organisms (22,30,37).  It is just one member of the mammalian family of sirtuins, which is 
composed of a total of seven proteins (Sirt1-7).  Sirt1 is an NAD+-dependent deacetylase, 
increasing its activity in response to rising cellular NAD+/NADH ratios. Capable of deacetylating 
a variety of substrates, Sirt1 has been shown to play a role in an assortment of physiological 
activities, such as tumorigenesis, aging, metabolism, and the control of gene expression (43).  
Moreover, recent work has begun to uncover a beneficial role for Sirt1 expression in the 
maintenance of skeletal muscle mass and function (237), indicating a potential for improving 
regeneration in various muscle pathologies. 
 One of the key targets of Sirt1 in skeletal muscle is the transcriptional coactivator 
peroxisome proliferator-activated γ coactivator-1α (PGC-1α) (7,15).  PGC-1α promotes the 
expression of genes related to mitochondrial biogenesis and oxidative metabolism in skeletal 
muscle, and its overexpression has been shown to increase fatigue resistance in muscles (25).   
PGC-1α also appears to have a protective role in conditions of muscle atrophy.  Transgenic 
mice overexpressing PGC-1α in skeletal muscle experienced decreased denervation and 
fasting-induced muscle atrophy responses (208), and were protected from age-associated 
muscle wasting (249).  This is most likely due to the reduced protein degradation that has been 
associated with PGC-1α overexpression (33).  Thus, the deacetylation of PGC-1α by Sirt1 is 
one potential pathway for the involvement of Sirt1 in the regulation of skeletal muscle mass and 
function.  Another downstream target of Sirt1 which may have a role in the regulation of skeletal 
muscle size and strength is NF-κB (19,28).  Activation of the NF-κB pathway alone has been 
shown to be sufficient to induce muscle wasting (6,39).  As Sirt1 activity inhibits the 
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transactivation of NF-κB on the p65 subunit (32,41), increasing Sirt1 may prove beneficial 
during periods of muscle wasting. 
 Recent research utilizing resveratrol, a known Sirt1 activator, has also provided insight 
into the possible benefits of Sirt1 in skeletal muscle maintenance.  In one study, resveratrol 
inhibited dexamethasone-induced MuRF1 and atrogin-1 expression in cultured myotubes, and 
these effects were dependent on Sirt1 expression (1).  Moreover, this study also provided 
evidence that resveratrol can attenuate increases in protein degradation as well as decreases in 
myotube diameter under these catabolic conditions (1).  In another study, resveratrol 
supplementation significantly reduced decreases in both muscle weight and fiber area of 
animals subjected to a period of hindlimb unloading (26).  Furthermore, resveratrol has been 
shown to increase muscle force under a variety of conditions (13,21,23,34), providing evidence 
that Sirt1 may be beneficial to both skeletal muscle size and function, which could potentially 
translate into improved muscle regeneration.    
 While there are a variety of models available to study muscle regeneration, one of the 
most reproducible methods involves the injection of myotoxins, such as cardiotoxin (CTX), 
directly into the individual muscle to be studied (12,16).  CTX, a peptide isolated from snake 
venom, is a protein kinase C-specific inhibitor that appears to disrupt membrane organization, 
induce the depolarization and contraction of muscle cells, and has the ability to lyse various cell 
types (52).  Utilizing this model, muscle degeneration has been observed to occur within one 
day of injection, mononuclear cell proliferation peaks 1-4 days following the injection, and 
myogenic cell differentiation and the formation of new myotubes occurs ~5-6 days following the 
CTX injection (52).  Therefore, in this study we examined both Sirt1-overexpression (Sirt1+/+) 
and Sirt1-knockdown (Sirt1-/-) transgenic animals at days 3 and 7 post-injection in order to 
determine the potential effects of Sirt1 on skeletal muscle regeneration.   It was hypothesized 
that Sirt1 overexpression would benefit muscle regeneration (i.e., strength and/or size), while 





Animals.  A total of 48 older-age (18-22 months) transgenic mice were used.  Sirt1-
overexpressing (Sirt1+/+) mice were generously obtained from Dr. Sadoshima (3). These mice 
were generated on an FVB background using the α-myosin heavy chain (α-MHC) promoter, 
which results in a mild overexpression of Sirt1 in fast fibers which contain α-MHC.  Muscle 
specific Sirt1-knockdown (Sirt1-/-) mice were generated by crossing 129-Sirt1tm1Ygu/J  (148) with 
a α-MHC cre mouse (Jackson labs, Cold Spring Harbor). This resulted in a knock down of Sirt1 
in fast contracting fibers of skeletal muscle. 
Twelve Sirt1-overexpressing (Sirt1+/+) mice and twelve Sirt1-knockdown (Sirt1-/-) mice 
were used to examine the effects of Sirt1 on muscle regeneration.  In addition, twelve mutant 
Sirt1 (Sirt1+/-) wild-type littermates were used as controls for each the Sirt1+/+ and Sirt1-/- mice.  
All animals were housed at 20˚C in barrier-controlled conditions under a 12:12 hour light-dark 
cycle.   Proper animal care standards were followed by adhering to the recommendations for the 
care of laboratory animals as advocated by the American Association for Accreditation of 
Laboratory Animal Care and by following the policies and procedures detailed in the Guide for 
the Care and Use of Laboratory Animals as published by the U.S. Department of Health and 
Human Services and proclaimed in the Animal Welfare Act (PL89-544, PL91-979, and PL94-
279).  All experimental procedures were approved by the Institutional Animal Care and Use 
Committee from the West Virginia University. 
 
Bromodeoxyuridine administration.  Five days prior to muscle injury, each animal received a 
15 mg Bromodeoxyuridine (BrdU; 5-bromo-2’-deoxyuridine) pellet (21-day release; Innovative 
Research; Sarasota, FL) in order to analyze cellular proliferation.  A small incision was made in 
the skin of the upper back of anesthetized (97% Oxygen/3% Isofluorane) animals whereupon 
the BrdU pellet was inserted subcutaneously.  The incision was closed with a wound clip 
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(MikRon Autoclip 9mm; Becton Dickinson; Sparks, MD) and the animal was allowed sufficient 
time to recover from anesthesia before being returned to its cage. 
 
Muscle injury and collection.  Cardiotoxin (CTX; from Naja Mossambica; Sigma) was 
prepared in sterile phosphate-buffered saline (PBS) at a concentration of 10 μM.  The hind limbs 
of anesthetized mice were carefully shaved and 75μL of CTX was injected into the exposed 
tibialis anterior (TA) muscle of the left leg.  Moreover, the TA muscle of the contralateral (i.e., 
right) leg was injected with 75μL of sterile PBS and was used as an intra-animal control.  All 
mice were carefully monitored following this procedure to ensure a full recovery from 
anesthetization.  Six animals from each group were then sacrificed either 3 or 7 days following 
the CTX injury.  On the respective day of sacrifice, TA muscles were surgically removed from 
anesthetized (97% Oxygen/3% Isofluorane) animals, blotted to remove excess fluid, weighed, 
flash frozen in liquid nitrogen cooled isopentane, and stored at -80°C for later analyses.  Once 
the muscles had been excised, the animals were killed by removing their heart with surgical 
scissors.    
 
In situ muscle physiological analyses.  In situ isometric muscle contractile properties were 
examined in the TA muscles of the mice immediately prior to removing the muscles and 
sacrificing the animals.  Mice were anesthetized (97% Oxygen/3% Isofluorane) and placed on 
their right side on a heated (37˚C) plate.  Utilizing surgical scissors, the distal tendons of all 
lower limb muscles except the TA were completely severed, ensuring that the TA was the only 
muscle which had control over any movements at the ankle joint.  The foot of one leg was then 
secured to a footplate attached to a servomotor (Model 6350*358; Cambridge Technology Inc., 
Cambridge, MA).  Dynamic Muscle Control (DMC) software (Aurora Scientific Inc., Aurora, 
Ontario, Canada) controlled the servomotor and maintained the correct angular position of the 
foot throughout.  TA muscle contractions were stimulated using a High-Power Bi-Phase Current 
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Stimulator (Aurora Scientific Inc.).  Peak isometric tetanic force (Po) was performed as 
previously described (7) and force-frequency isometric force records were obtained by 
stimulating the muscle at 5, 10, 20, 50, 75 and 100 Hz, with 3 minutes of rest between each 
contraction.  Once the first leg had finished, all distal muscle tendons from the lower 
contralateral leg except the TA were severed and the second leg was subsequently run through 
the aforementioned protocol.  All contractile and fatigue measurements were analyzed off line 
using commercial software (DMI, Aurora Scientific). 
 
Fiber cross-sectional area.  Muscle fiber cross-sectional area (CSA) measurements were 
utilized to determine the extent of muscle fiber regeneration in the TA muscles of the CTX-
injured and control muscles of the mice.  CSA was determined by planimetry from three non-
overlapping regions of each tissue cross-section stained for lamina, utilizing a Zeiss LSM 510 
Meta confocal microscope (Carl Zeiss Microimaging Inc.; Thornwood, NY) with a 10X objective.  
Mean myofiber CSA measurements were calculated with the ImageJ software (NIH; Frederick, 
MD).  Furthermore, we used these individual CSA measurements to determine the total relative 
area of each field which contained regenerating myofibers.  To accomplish this, we used the 
sum area of all the regenerating myofibers within a given field, and expressed this value as a 
percentage of the total area of the respective field.  Thus, we were able to analyze both the 
mean size of the regenerating fibers as well as the relative extent to which these fibers were 
regenerating throughout the whole TA muscle cross-section. 
 
Fiber characteristics.  Muscle fiber type analyses were performed in order to examine the 
development of various myosin heavy chain (MyHC) isoforms in the regenerating fibers.  Frozen 
tissue cross sections measuring 8-μm thick from the mid-belly of the muscles were mounted on 
charged microscope slides (Fisher Scientific; Pittsburgh, PA) and stored at -80°C.  Briefly, slides 
were air-dried 30 minutes, washed 10 minutes in PBS, and incubated 30 minutes with 4% 
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bovine serum albumin (BSA) in PBS at room temperature (RT).  Sections were then incubated 
overnight at 4°C with antibodies directed against laminin (MAB1914; Millipore; Temecula, CA) to 
visualize the basal lamina of each muscle fiber, as well as one of the following individual MyHC 
antibodies: BA-D5 (for MyHC I; Developmental Studies Hybridoma Bank; Iowa City, IA), SC-71 
(for MyHC IIA; DSHB), BF-F3 (for MyHC IIB; DSHB), and developmental MyHC (VP-M664; 
Vector Laboratories; Burlingame, CA).  On the following  day, slides were washed in PBS and 
incubated 1 hour at 37°C with secondary antibodies of donkey anti-rat rhodamine (712-025-150; 
Jackson ImmunoResearch Laboratories; West Grove, PA) to visualize the basal lamina and 
Alexa Fluor 488 (A10680; Invitrogen; Eugene, OR) to visualize the MyHC-positive fibers.  The 
sections were then mounted with 4', 6-diamidino-2-phenylindole (DAPI) (Vectashield Mounting 
Medium; Vector Laboratories; Burlingame, CA) in order to visualize the myonuclei.  Three 
images from non-overlapping regions of each tissue cross-section stained for individual MyHC’s 
were used for fiber type proportions.  All images were taken with a Zeiss LSM 510 Meta 
confocal microscope (Carl Zeiss) using a 10X objective.  Fiber types were expressed as a 
proportion of MyHC-positive fibers to total muscle fibers for each individual MyHC examined. 
 
BrdU detection.  Frozen tissue cross sections measuring 8-μm thick from the plantaris muscle 
was mounted on charged microscope slides (Fisher Scientific).  Briefly, frozen tissue sections 
were air dried, fixed in methanol:acetone (1:1) at -20°C, and permeabilized with 0.4% Triton X-
100 in PBS.  Sections were then denatured using Reagent 2 and blocked with Reagent 3, both 
of which being components of the Calbiochem BrdU Immunohistochemistry System (HCS30; 
EMD Biosciences, Inc.; La Jolla, CA).  Sections were incubated overnight in a biotinylated 
mouse anti-BrdU primary antibody provided in the Calbiochem kit.  The tissue sections were 
then incubated with Fluorescein Avidin DCS (A-2011; Vector Laboratories, Inc.; Burlingame, 
CA) and subsequently blocked in normal goat serum.  They were then incubated overnight in rat 
anti-lamina monoclonal (Millipore) antibody. Sections were incubated the following day with 
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donkey anti-rat rhodamine conjugated (Jackson ImmunoResearch) secondary antibodies in a 
humidified chamber at 37°C for 1 hour in the dark.  Finally, sections were washed in PBS and 
mounted with DAPI mounting medium (Vectashield) in order to visualize nuclei.  
Immunofluorescence was visualized with a Zeiss LSM 510 Meta confocal microscope (Carl 
Zeiss).  Images were taken from three non-overlapping regions of each tissue section with a 
10X objective.   
 
Identification of apoptotic nuclei.  Frozen tissue cross sections measuring 8-μm thick from 
the TA muscles were mounted on charged microscope slides (Fisher Scientific).  Fluorescent 
labeling of terminal dUTP nick-end labeling (TUNEL) with lamina allowed the detection of 
apoptotic nuclei in the muscle sections. This was accomplished using a slight modification to the 
method previously reported for our lab (36).  Briefly, the tissue sections were air dried, fixed with 
4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in PBS for 30 minutes each at 
room temperature.  The tissues were incubated overnight at 4°C in a rat anti-lamina monoclonal 
antibody (Millipore) to visualize the basal lamina of each muscle fiber. The sections were 
incubated the following day with donkey anti-rat rhodamine conjugated secondary antibody 
(Jackson ImmunoResearch), along with the TUNEL reaction mixture (11-684-795-910; Roche 
Diagnostics; Indianapolis, IN) in a humidified chamber at 37°C for 1 hour in the dark. The 
exclusion of the TdT enzyme in the TUNEL reaction mixture on one of the tissue sections on 
each slide was included as a negative control. The sections were mounted with DAPI (Vector 
Laboratories) and viewed using a 10X objective on the Zeiss LSM 510 Meta confocal 
microscope (Carl Zeiss).  The numbers of TUNEL and DAPI-positive nuclei that were 
immediately adjacent to, or beneath the basal lamina were counted.   Data is expressed as an 
apoptotic index, which is the quantity of TUNEL-positive nuclei per 100 myofibers. The apoptotic 




Statistical analysis.  The results are reported as means ± standard deviation (SD).  
Differences in means between groups were determined by multiple analysis of variance 
(MANOVA) Hotelling's T-Square test. Bonferroni post hoc analysis was performed between 
significant means.  Chi-squared analyses was conducted between experimental groups for the 








Body and muscle weights.  Throughout the experimental period, all animals appeared visibly 
healthy and neither the Sirt1-/- nor Sirt1+/+ transgenic animals displayed any apparent phenotypic 
abnormalities.  All animals were weighed immediately prior to muscle injury as well as on their 
respective day of sacrifice.  No differences in bodyweight were observed between these two 
time points and therefore only the weights obtained on the day of sacrifice are presented in 
Table 1.  On day 3 post-injury, there were no significant differences in bodyweight between the 
WT (34.97 ± 2.62 g) and Sirt1-/- (36.46 ± 6.57 g) animals on the Sirt1-/- background.   As 
expected, the CTX-injured TA muscle wet weights normalized to bodyweight were significantly 
reduced as compared to the control muscle of each individual animal.  The normalized weights 
of these WT animals were 1.15 ± 0.20 mg/g for the injured muscle, compared to 1.86 ± 0.14 
mg/g for the respective control muscle.  The normalized weights for the Sirt1-/- animals were 
0.83 ± 0.10 mg/g and 1.33 ± 0.17 mg/g for the injured and control muscles respectively, both of 
which were significantly reduced as compared to each of the respective WT muscle values.  
However, when the values for the injured muscles were expressed as a percentage of the 
values for each individual animals’ respective control muscles, this difference disappeared.  The 
wet muscle weight of the injured muscles for the WT and Sirt1-/- animals were 62.14 ± 10.22% 
and 62.05 ± 4.84% of the control muscles, respectively. 
There were also no differences between the body weights of the WT (32.53 ± 1.95 g) 
and Sirt1-/- (31.40 ± 4.13 g) animals on day 7 post-injury.  The normalized wet weights from the 
injured muscles of both the WT (1.21 ± 0.12 mg/g) and Sirt1-/- (0.83 ± 0.10 mg/g) animals were 
still significantly smaller than that of the control muscles, which were 1.90 ± 0.20 mg/g and 1.37 
± 0.13 mg/g for the WT and Sirt1-/- animals, respectively.  As with the animals on day 3 post-
injury, both the injured and control muscles of the WT mice were significantly larger than their 
Sirt1-/- counterparts.  However, expressing the injured muscles as a percentage of their 
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respective control muscles in both the WT (62.00 ± 5.88%) and Sirt1-/- (60.98 ± 8.35%) animals 
effectively eliminated these differences. 
 Of the animals on the Sirt1+/+ background, there were no differences in bodyweight 
between the WT and Sirt1+/+ animals at either day 3 or 7 post-injury.  On day 3, the bodyweights 
were 45.23 ± 9.88 g and 45.98 ± 14.25 g for the WT and Sirt1+/+ animals, respectively.  
Likewise, 7 days following injury the WT and Sirt1+/+ animals weighed 38.47 ± 9.18 g and 45.23 
± 5.32 g, respectively.  The injured muscles of both the WT and Sirt1+/+ animals were 
significantly reduced at days 3 and 7, as compared to their respective control muscles.  
However, no differences were observed in the normalized weights of the injured muscles 
between the two groups.  On day 3 post-injury, the normalized muscle wet weights of the WT 
and Sirt1+/+ animals were 0.82 ± 0.15 mg/g and 0.85 ± 0.21 mg/g, respectively.  This is a 
significant decrease compared to the respective uninjured muscles of both the WT and Sirt1+/+ 
animals, which were 1.28 ± 0.14 mg/g and 1.32 ± 0.29 mg/g, respectively.  On day 7 post-injury, 
the weights from the WT (0.79 ± 0.23 mg/g) and Sirt1+/+ (0.94 ± 0.17 mg/g) injured muscles 
were significantly smaller than that of the uninjured muscles, which were 1.30 ± 0.16 mg/g and 
1.35 ± 0.17 mg/g for the WT and Sirt1+/+ animals, respectively.   
 
Muscle force characteristics.  Immediately prior to each individual animal being sacrificed, the 
in situ force characteristics of the TA muscles were obtained for analysis.  We first examined the 
maximal tetanic force for both the injured and control muscles.  These values were determined 
at a frequency of 100 Hz and all forces were normalized to the wet weight of the respective TA 
muscle the force was measured from.  In the Sirt1-/- animals, no differences in normalized 
maximal tetanic force were found in the control muscles of the animals on day 3 post-injury, with 
values of 1.79 ± 0.41 mN/mg and 2.32 ± 0.66 mN/mg for the WT and Sirt1-/- animals, 
respectively (Figure 1A).  While there were no differences between them, the forces produced in 
both the injured WT (0.51 ± 0.35 mN/mg) and Sirt1-/- (0.90 ± 0.46 mN/mg) muscles were 
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significantly smaller than those of their respective control muscles.  On day 7, these values 
remained largely consistent and once again, no differences were observed between the WT 
(2.48 ± 0.24 mN/mg) and Sirt1-/- (2.15 ± 0.49 mN/mg) control muscles (Figure 1B).  The 
maximal forces produced in the injured muscles of both the WT (0.74 ± 0.25 mN/mg) and Sirt1-/- 
(0.66 ± 0.28 mN/mg) animals were significantly smaller than the respective control muscle 
forces, however, there were no differences between these two groups of injured muscles. 
 In the animals bred on the Sirt1+/+ background, no differences in normalized maximal 
tetanic force were observed on day 3 post-injury in the control muscles of the WT (1.85 ± 0.24 
mN/mg) and Sirt1+/+ (1.79 ± 0.43 mN/mg) animals (Figure 1A).  Whereas only the forces from 
the injured muscles of the WT (0.42 ± 0.17 mN/mg) animals were significantly smaller than their 
respective control values, the maximal tetanic force from the Sirt1+/+ (1.26 ± 0.40 mN/mg) 
animals was significantly greater than that of the WT animals.  
 On day 7 post-injury, the maximal force produced in the control muscles of the WT (1.36 
± 0.25 mN/mg) and Sirt1+/+ (1.52 ± 0.31 mN/mg) animals did not differ (Figure 1B).  However, 
only the maximal force from the injured muscle of the WT (0.64 ± 0.40 mN/mg) group was 
significantly smaller than its respective control muscle force, and the force from the injured 
muscle of the Sirt+/+ (1.24 ± 0.58 mN/mg) group did not differ from that of its’ control muscles.   
 Next, we plotted a force-frequency curve of the muscle force data collected from both 
the control and injured TA muscles on days 3 and 7 post-injury.  For this curve, muscle forces at 
a given frequency are expressed as a percentage of the force produced at 100 Hz.  In the 
animals bred on the Sirt1-/- background, the only differences in the force-frequency curve were 
observed on day 3 post-injury (Figure 2A).  On this day, the injured muscle from the WT animals 
had significantly greater relative forces than their respective control muscles, as well as the 
injured muscles from the Sirt1-/- animals at frequencies of 5 and 10 Hz.  However, these 




 In the animals on the Sirt1+/+ background, there were no significant differences noted on 
day 3 post-injury at any of the frequencies, either between the groups of animals or within them 
(Figure 2C).  On day 7, there was only one significantly different value observed.  At a 
frequency of 75 Hz, the injured muscles in the WT animals produced a significantly smaller 
relative force than did their respective control muscles (Figure 2D).  No other differences were 
observed between or within any of the groups at any other frequency examined.   
      
Muscle fiber morphology.  TA muscles were analyzed both 3 and 7 days following muscle 
injury to track the progress of fiber regeneration.  The mean CSA’s of the control and 
regenerating myofibers were determined by planimetry from sections stained for lamina.  In the 
Sirt1-/- background groups, it is interesting to note that the mean CSA of the Sirt1-/- control fibers 
were significantly (p<.01) smaller than that of the WT control fibers at both 3 and 7 days post-
injury (Figures 3A, 3B).  On day 3 post-injury, the mean fiber CSA from the WT control muscles 
was 1,375.76 ± 229.88 μm2, as compared to 865.40 ± 92.25 μm2 from the Sirt1-/- control 
muscles.  However, although the mean fiber CSA from all of the injured muscles were 
significantly smaller than their respective control muscles, no differences were found between 
the injured WT and Sirt1-/- muscles at either 3 or 7 days post-injury.  On day 3, the mean CSA 
from the injured WT fibers measured 163.50 ± 43.25 μm2, while the injured Sirt1-/- fibers 
measured 201.75 ± 36.72 μm2 (Figure 3A).  On day 7, the injured muscles continued to 
regenerate, enlarging to 428.89 ± 92.25 μm2 for the WT fibers and 332.64 ± 93.13 μm2 for the 
Sirt1-/- fibers (Figure 3B). 
 In the Sirt1+/+ background animals, no differences in fiber CSA were noted between the 
control muscles from the WT and Sirt1+/+ animals at either day 3 or 7 post-injury.  On day 3, the 
fibers measured 1,400.17 ± 235.44 μm2 and 1,405.40 ± 36.44 μm2 in the WT and Sirt1+/+ control 
muscles, respectively (Figure 3A).  On day 7, these values were 1,149.90 ± 177.64 μm2 and 
1,149.07 ± 177.64 μm2 for the WT and Sirt1+/+ animals, respectively (Figure 3B).  As expected, 
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the regenerating fibers from both the WT and Sirt1+/+ animals were significantly smaller than 
their respective control muscle fibers both 3 and 7 days following the CTX administration.  
However, there were no differences between the WT and Sirt1+/+ animals’ mean fiber CSA from 
the injured muscles on either of these days.  On day 3, the mean fiber CSA from the injured 
muscles of the WT and Sirt1+/+ animals measured 301.53 ± 111.42 μm2 and 257.93 ± 11.54 
μm2, respectively (Figure 3A).  By day 7 post-injury, these measurements increased to 373.10 ± 
99.26 μm2 and 408.30 ± 116.65 μm2 for the WT and Sirt1+/+ animals, respectively (Figure 3B). 
 Next, we examined the relative area within the TA muscle belly which actually contained 
regenerating myofibers in order to gain a fuller understanding as to the extent of muscle 
regeneration than what could be obtained with the mean myofiber CSA measurements alone.  
To accomplish this, we expressed the sum of all of the myofiber CSA’s in a given field as a 
percentage of the total area of this field from which these fibers were measured.  In the Sirt1-/- 
background animals on day 3 post-injury, it was interesting to note that the control muscles of 
the Sirt1-/- (63.44 ± 7.80%) animals had significantly less relative myofiber area per field than did 
their respective WT (75.81 ± 11.13%) counterparts (Figure 3C).  Although they encompassed a 
significantly smaller percentage of myofiber area per field than the respective control muscles, 
no differences were found between the injured muscles from the WT (9.54 ± 3.74%) and Sirt1-/- 
(14.26 ± 4.44%) animals on day 3.  On day 7, the control muscles of the Sirt1-/- (59.04 ± 
19.48%) animals maintained a smaller percentage of myofiber area per field than did the WT 
(71.03 ± 13.23%) group, although here it did not reach statistical significance (Figure 3D).  
Similar to day 3 post-injury, both the WT (26.15 ± 6.68%) and Sirt1-/- (19.25 ± 6.65%) groups 
had significantly reduced total myofiber areas than did their respective control muscles, 
although no differences were found between these regenerating muscles on day 7.   
 In the Sirt1+/+ groups, no differences were found in the total myofiber area per field 
between the WT (59.09 ± 21.70%) and Sirt1+/+ (58.72 ± 15.37%) groups on day 3 post-injury 
(Figure 3C).  As expected, both the WT (17.10 ± 5.10%) and Sirt1+/+ (7.81 ± 2.61%) groups had 
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significantly reduced total myofiber areas per field in the injured muscles as compared to their 
respective control muscles.  Moreover, it was determined that these regenerating muscles in the 
Sirt1+/+ animals had a significantly (p<.01) smaller total myofiber area per field than did the WT 
group.  On day 7 post-injury, no differences existed between the control muscles of the WT 
(67.36 ± 13.82%) and Sirt1+/+ (66.32 ± 10.34%) animals (Figure 3D).  Although both the injured 
WT (34.20 ± 6.48%) and Sirt1+/+ (25.29 ± 10.58%) muscles had a significantly smaller total 
myofiber area than that of their respective control muscles, no differences were observed 
between the regenerating muscles of these two groups. 
 
Fiber composition.  Both injured and control muscles were examined to determine the relative 
fiber MyHC composition of each at the different time points following muscle injury.  In the Sirt1-/- 
animals, the composition of the regenerating fibers was very similar to that of the injured WT 
muscles both 3 and 7 days post-injury (Figures 4A, 4B).  The regenerating muscles of each of 
these animals consisted of a low overall percentage of type I, IIA, and IIB MyHC fibers, while the 
great majority of these tested positive for developmental fibers.  However, there was one 
difference to note, which occurred on day 7.  Upon examination of the type IIB fibers, it was 
determined that the injured muscles of the WT (34.1 ± 6.1%) animals had significantly more of 
these fibers than did the Sirt1-/- (6.1 ±3.0%) animals (Figure 4B).  No other differences in fiber 
composition were observed in these animals.   
 In the Sirt1+/+ background, the same general pattern repeated itself.  On both days 3 and 
7 post-injury, the only differences observed between the injured muscles of the Sirt1+/+ and WT 
animals were in the type IIB MyHC fiber composition.  On day 3, the relative composition of type 
IIB fibers was significantly greater in the WT (4.1 ± 2.1%) compared to the Sirt1+/+ animals, 
which did not have any of these fibers at this stage (Figure 4C).  This gap widened on day 7 
post-injury, with the composition of type IIB fibers remaining low in the Sirt1+/+ (16.8 ± 7.7%) 
animals, while it returned to that of the control muscles in the WT (43.0 ± 9.8%) animals (Figure 
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4D).  As with the animals on the Sirt1-/- background, the only differences observed in fiber 
composition were in the type IIB fibers.   
       
Satellite Cells.  Satellite cells are an integral component of proper skeletal muscle 
regeneration.  Therefore, we examined several satellite cell markers at both days 3 and 7 post-
injury.  Implanting a BrdU pellet into each of the animals five days prior to muscle injury allowed 
us to track newly synthesized satellite cells throughout the regeneration period.  As expected, 
the control muscles from all of the animals had minimal BrdU incorporation, as satellite cells 
remain quiescent under basal conditions.  However, BrdU incorporation was significantly 
increased in all of the injured muscles, as satellite cells were activated in these muscles in an 
attempt to repair the damaged fibers.   
 On day 3 post-injury, the quantity of BrdU-positive nuclei per 100 fibers was not different 
in the TA of Sirt1-/- (4.30 ± 1.33) animals than it was in their WT (2.67 ± 1.05) counterparts 
(Figure 5A).  Likewise, the injured muscles from the Sirt1+/+ (2.44 ± 1.44) animals had 
approximately the same proportion of BrdU-positive nuclei as their respective WT (4.64 ± 1.85) 
littermates. On day 7 post-injury, the injured muscles of the Sirt1-/- (3.90 ± 2.27) animals once 
again were not different than the WT (2.09 ± 1.00) animals (Figure 5B).  On the Sirt1+/+ 
background, there were no differences noted between the injured muscles of the WT (2.76 ± 
1.60) and Sirt1+/+ (2.18 ± 1.48) animals.    
 
Apoptosis.  To determine if apoptosis played a role in hindering muscle regeneration we 
performed a TUNEL assay, which detects DNA strand breaks generated during apoptosis.  We 
expressed the results of the assay in a TUNEL index, namely, the quantity of TUNEL-positive 
nuclei per 100 myofibers.  There was a significant increase in apoptotic nuclei in the 
regenerating myofibers of all the animals.  On the Sirt1-/- background on day 3 post-injury, the 
TUNEL index of the WT animals increased from 0.14 ± 0.10 in the control muscles to 3.99 ± 
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2.03 in the injured muscles (Figure 6A).  Likewise, the TUNEL index increased from 0.32 ± 0.24 
in the control muscles to 3.18 ± 2.29 in the injured muscles of the Sirt1-/- animals.  However, no 
differences were determined to exist between either the control or injured muscles of the WT 
and Sirt1-/- groups. 
 On day 7, the same pattern appeared as with day 3.  Muscles from the WT animals 
increased their respective TUNEL index from 0.04 ± 0.08 in the control muscles to 4.18 ± 1.40 
in the injured muscles (Figure 6B).  Similarly, the index was 0.22 ± 0.21 in the control muscles 
of the Sirt1-/- animals, and increased to 3.82 ± 1.56 in the injured muscles of these animals.  
Once again, there were no differences noted when comparing the control and injured muscles 
of the WT animals with that of the respective muscles from the Sirt1-/- animals. 
 In the animals bred on the Sirt1+/+ background, there were no differences in the TUNEL 
index between the WT (0.08 ± 0.13) and Sirt1+/+ (0.05 ± 0.10) control muscles on day 3 post-
injury (Figure 6A).  Moreover, although each groups’ index was significantly increased from the 
respective control muscles, there were no differences between the injured muscles of the WT 
(3.93 ± 1.55) and Sirt1+/+ (2.60 ± 0.90) groups.  These trends persisted into day 7 post-injury.  
The index from the control muscles of the WT animals on this day increased from 0.03 ± 0.09 to 
3.04 ± 1.64 in the injured muscles (Figure 6B).  In the Sirt1+/+ animals, the TUNEL index was 
found to be 0.03 ± 0.08 in the control muscles, increasing to 3.21 ± 1.89 in the injured muscles.  
However, there were no differences observed between the WT and Sirt1+/+ groups when 
comparing their respective control and regenerating muscles.   









 Sirt1, the mammalian homolog of the yeast Sir2, has been implicated in lifespan 
extension, neurodegenerative and cardiovascular disease, cancer, and certain metabolic 
disorders (107).  However, the role of Sirt1 in the maintenance and regeneration of skeletal 
muscle is much less understood.  Here we utilized a CTX-induced muscle injury model to 
examine the effects of Sirt1 on skeletal muscle regeneration in older-age transgenic Sirt1 
animals.   
  
Sirt1 has minimal effects on muscle mass during regeneration 
 On both days 3 and 7 post-injury, there was no difference in the bodyweights of either 
the Sirt1-/- or Sirt1+/+ animals and their respective WT counterparts.  As expected (52), the CTX 
caused considerable damage to the TA muscles within a short time, as evidenced by 
significantly smaller normalized muscle wet weights observed 3 days following the injury 
protocol.  It was interesting to note that both the injured and control muscles from the Sirt1-/- 
animals had significantly smaller normalized wet muscle weights than the respective WT 
muscles on both days 3 and 7 post-injury.  However, the injured and control muscle weights of 
the Sirt1-/- animals did not differ from the values of those in the respective muscles of the Sirt1+/+ 
and WT animals bred on the Sirt1+/+ background.  Moreover, when the injured muscles were 
expressed as a proportion to the weight of the control muscles the differences were nullified, 
suggesting that the injured muscles of the Sirt1-/- animals regenerated as well as the WT 
muscles in terms of wet muscle weight.  In the animals bred on the Sirt1+/+ background, there 
were no differences observed in the normalized wet muscle weights between the WT and 
Sirt1+/+ animals on either day 3 or 7.  Therefore, Sirt1 may have a very limited impact on the 
overall mass of regenerating myofibers. It is recognized that both Sirt1 knockdown and 
overexpression occurred in only the fast contracting fibers, and while the majority of fibers in the 
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TA muscle were composed of fast fibers, a small percentage of type I fibers would have been 
unaffected by the genetic manipulation. It is not clear from this study if knockdown or 
overexpression of Sirt1 in all muscle fibers would have altered the overall conclusions, but this 
bears testing in future studies.  
 
Sirt1 overexpression increases force in regenerating muscles   
 Next, we examined various force characteristics to determine any effects Sirt1 could 
possibly have on the contractile properties of regenerating muscles.  We first examined the 
maximal tetanic forces, which were normalized to the wet weight of each individual TA muscle 
being examined.  As expected with muscle injury (11,27), the force output of the injured muscle 
was less than that of the control muscle.  This was true even after normalizing all of the forces 
to the wet weight of each individual muscle.  In the animals on the Sirt1-/- background, there 
were no differences between the normalized force from either the control or injured muscles 
when comparing the WT and Sirt1-/- animals at either day 3 or 7 post-injury.  However, the 
forces from the injured muscles were significantly smaller than that of the control muscles for 
each individual animal, indicating that the CTX treatment generated functional deficits in the 
muscles.  Based on our data collected from the animals bred on the Sirt1+/+ background, it 
appears that overexpression of Sirt1 may improve functional muscle regeneration, providing a 
quicker recovery of strength during the initial stages of recovery. 
 On day 3 post-injury, both the injured muscles from the WT and Sirt1+/+ animals 
produced significantly less force than their respective control muscles.  However, the mean 
normalized tetanic force of the injured Sirt1+/+ muscles was three-fold greater than that of the 
injured WT muscle.  On day 7, the tetanic force of the Sirt1+/+ muscles remained consistent with 
that observed on day 3.  At this time point, the tetanic force from these muscles was no longer 
significantly smaller than that of the respective control muscles, although the mean was still 
slightly reduced.  However, the force produced in the injured muscles of the Sirt1+/+ animals was 
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significantly greater than that of the injured WT muscles, which again produced significantly less 
force than their respective control muscles.    
       While our study suggests that decreasing Sirt1 expression does not have an effect on force 
production during muscle regeneration, our findings that upregulating its expression can 
increase muscle force is in agreement with several previous studies.  In these studies 
(13,21,23,34), it was shown that supplementation with resveratrol, a Sirt1 activator, provided 
significant benefits in skeletal muscle force production under a variety of physiological 
conditions.  Thus, the results from our present study offer additional support for the positive role 
of increasing Sirt1 expression on muscle force.  Moreover, the neutral effect on muscle force we 
observed when decreasing the expression of Sirt1 suggests that while it may not be important 
for muscle function during normal regeneration, increasing Sirt1 expression may provide a 
shortened functional recovery following muscle injury.  
 We next analyzed a force-frequency curve to examine additional contractile properties in 
the regenerating muscles of the transgenic animals.  On day 3 post-injury, the only significant 
differences that occurred were in the animals on the Sirt1-/- background.  At 5 and 10 Hz, the 
injured WT muscles had a force-frequency curve which was shifted significantly to the left of 
both their respective control muscles and the injured muscles of the Sirt1-/- animals.  This 
leftward shift in the force-frequency curve is indicative of a slower muscle phenotype.  However, 
this leftward shift was abolished by day 7 and there were no differences between any of the 
force-frequency curves plotted on this day.  In the animals on the Sirt1+/+ background, the force-
frequency curves of all the muscles examined remained largely consistent on both days 3 and 
7.  The regenerating muscles from the Sirt1+/+ animals had curves at both days 3 and 7 post-
injury which were no different from what was observed in the respective control muscles or in 
any of the WT muscles.  Thus, no clear phenotypic changes were observed in the muscle 
contractile properties of the Sirt1+/+ animals.   
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 It was interesting to note that none of our force-frequency curves uncovered any 
significant differences between the WT animals and either of the Sirt1 transgenic animal groups.  
In a recent study by Jackson et al. (20), administration of resveratrol to aged animals showed a 
rightward shift in a force-frequency curve.  This would suggest a shift to a fast-muscle 
phenotype and would provide additional support for the increased maximal tetanic force 
production we observed in our Sirt1+/+ animals.  However, we saw no such shift in the force-
frequency curves from these animals in our present study.  One possible explanation of the 
Jackson et al. findings is that the force-frequency curve shift was observed in aged animals 
under homeostatic conditions, unlike our present study in which there was a significant 
perturbation applied to the muscles to induce regeneration.  Moreover, it is plausible that the 
muscles in our animals were not recovered to an extent where any possible differences in the 
force-frequency curves could emerge.   
 
Sirt1 in muscle fiber regeneration    
 In order to determine how well the different Sirt1 muscles regenerated, we examined 
both the mean CSA of the fibers as well as the relative area within the muscle belly which was 
filled with myofibers.  When examining the mean CSA’s, it was interesting to note that while 
there were no differences between the area of the regenerating WT and Sirt1-/- muscles, the 
control muscles of the Sirt1-/- animals were significantly smaller than those of the WT animals at 
both days 3 and 7 post-injury.  These findings are consistent with what we observed when 
calculating the relative area within a muscle fiber which contained myofibers as well.  There 
were no differences between the injured WT and Sirt1-/- muscles at either day 3 or 7 post-injury.  
However, the relative area of the control muscles which contained myofibers was significantly 
less in the Sirt1-/- animals than in the WT animals at day 3.  While these values did not reach 
statistical significance on day 7, the total relative myofiber area of the Sirt1-/- animals was still 
smaller than that of the WT animals.  This finding may be partly explained by recent research in 
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which it was observed that Sirt1 activity and expression were downregulated in various models 
of muscles wasting (2,31).  While our model was very much different than that of muscle 
wasting, these combined observations may allow for the speculation that there is a potential role 
of Sirt1 expression in general skeletal muscle maintenance.   
  In the animals bred on the Sirt1+/+ background, no such differences in the control 
muscles existed between the two groups in either mean CSA or relative total myofiber area.  On 
both days 3 and 7 post-injury, the mean CSA from the injured muscles of the Sirt1+/+ animals 
was no different than the WT muscles.  In contrast, the relative total myofiber area of the Sirt1+/+ 
muscles was significantly less than that of the WT muscles on day 3.  However, this difference 
between the injured muscles was eliminated by day 7 post-injury.  This was an unexpected 
finding, given that several studies utilizing the Sirt1 activator resveratrol have suggested that 
Sirt1 is able to protect skeletal muscle from several catabolic conditions (10,18,26,35).  The 
results from these studies are likely attributed to the ability of Sirt1 to attenuate increases in 
protein degradation and the expression of the atrophy-related ligases MuRF1 and atrogin-1 
during catabolic conditions (1).  Thus, the results from these prior studies in combination with 
our present data appear to suggest that although Sirt1 may be beneficial during periods of 
skeletal muscle catabolism by attenuating proteolysis and the expression of atrophy-related 
ligases, it may not have any significant effects on the early hypertrophy of regenerating 
muscles. 
 Furthermore, we determined the fiber type proportions of each of the muscles.  The 
largest proportion of fiber types in the regenerating muscles of all groups was developmental 
fibers.  This was expected at this early stage of recovery, as the muscles did not have enough 
time to convert to full-fledged MyHC fiber types.  However, no differences existed between any 
of the groups in the proportion of developmental fiber types at either 3 or 7 days post-injury.  
Furthermore, gain or loss of Sirt1 expression had no effect on either type I or IIA MyHC fiber 
composition.  Surprisingly, both the Sirt1+/+ and Sirt1-/- animals had a smaller proportion of type 
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IIB fibers in the injured muscles than the injured muscles of their respective WT mice.  It 
therefore is likely that Sirt1 plays a role in the regeneration of fast-twitch MyHC fibers, although 
the mechanism is unclear at this time.           
 
Satellite cells 
 Satellite cells are skeletal muscle stem cells that are activated when there is a sufficient 
perturbation to the tissue.  In order to repair the damaged tissue, satellite cells proliferate, 
differentiate, fuse to existing myofibers, and then begin to hypertrophy in an attempt to restore 
muscle fiber size and function.  In a 2003 study by Fulco et al. (14), it was suggested that Sirt1 
may inhibit differentiation through the repression of the myogenic transcription factor MyoD.  
However, decreasing levels of NAD+ during differentiation may decrease Sirt1 levels, thereby 
allowing normal differentiation to proceed (14).  Moreover, Sirt1 has been shown to increase the 
proliferation of satellite cells (198), possibly providing an increased stimulus for effective fiber 
regeneration.  
  In the present study, we did not see an increase in BrdU-labeled nuclei in the animals 
overexpressing Sirt1 at either 3 or 7 days post-injury.  Likewise, decreased Sirt1 expression in 
the Sirt1-/- animals had no effect on the amount of BrdU labeling observed in the regenerating 
muscles of these animals as compared to the injured WT muscles.  The lack of any differences 
in the injured muscles from either the Sirt1+/+ or Sirt1-/- animals cannot be explained by the loss 
or protection of myonuclei from apoptosis as we did not observe any variance in apoptotic 
signaling determined via TUNEL staining.  Thus, our in vivo model could neither confirm nor 
deny the previous findings of the effects of Sirt1 expression on satellite cell function observed 
under in vitro conditions.  Therefore, further in vivo work needs to be completed before any 
conclusions may be made on what role, if any, Sirt1 expression has on satellite cell activity and 






 Our present study was novel in that it attempted to examine the effects of manipulating 
Sirt1 expression on skeletal muscle regeneration in an in vivo model of muscle injury.  Although 
Sirt1 did not play a role in muscle mass or fiber area during regeneration, increasing its’ 
expression imparted beneficial effects to the force characteristics of the muscle.  The increased 
force production which coincided with elevated Sirt1 expression may translate to improved 
functional muscle recovery following injury or disruptions in normal muscle homeostasis in 
clinical populations.  Therefore, further work in which Sirt1 expression is increased 
experimentally should be investigated in order to evaluate its efficacy in treating various clinical 
populations such as the elderly in response to extended periods of disuse.  Moreover, our study 
failed to show a correlation between Sirt1 expression and satellite cell activity.  It is presently 
unknown if Sirt1 has an effect on this activity at the organism level, as previous research into 
this area has only involved in vitro work.  Future work specifically aimed at this utilizing in vivo 
models may provide a more comprehensive assessment of any potential effects of Sirt1 on 
satellite cell activity.  
 Our overall results from this study indicate that although Sirt1 expression may not affect 
muscle morphology, its effects on force production may be useful in treating various conditions 
which require muscle regeneration.  It would be clinically valuable if Sirt1 is able to provide a 
shortened functional recovery in response to muscle perturbations.  Therefore, or current 
findings may be useful as a base for further exploration into the potential of Sirt1 as an effective 








Table 1.  Bodyweight and muscle wet weight measurements from each of the genotypes at both 
3 and 7 days post-injury.  * P<.05 vs. respective injured WT, # P<.05 injured vs. respective 








Figure 1.  A,B)  The maximal tetanic force of each genotype was examined at both days 3 (A) 
and 7 (B) post-injury.  Individual forces were normalized to the muscle weights of each animal.   
* P<.05 vs. injured WT, # P<.05 injured vs. respective control.  
 
Figure 2.  A,B)  A force-frequency curve was developed for the Sirt1-/- animals at both 3 (A) and 
7 (B) days post-injury.  C,D)  A force-frequency curve was developed for the Sirt1+/+ animals at 
both 3 (C) and 7 (D) days post-injury.  Values are the force produced at each given frequency 
expressed as a percentage of the force produced at 100 Hz for each individual animal.  * P<.05 
injured vs. injured at given frequency, # P<.05 vs. respective control at given frequency.    
 
Figure 3.  Mean myofiber cross-sectional area (CSA) and total myofibril area analysis were 
performed for each genotype.  A,B)  Fiber CSA was determined by planimetery on both days 3 
(A) and 7 (B) post-injury.  C,D)  Total myofibril area is defined as the total area within a given 
field that contains myofibers and was determined both 3 (C) and 7 (D) days post-injury in each 
of the groups.  * P<.05 vs. injured WT, # P<.05 injured vs. respective control, † P<.05 vs. WT 
control.   
 
Figure 4.  The MyHC fiber composition of both the injured and control TA muscles were 
analyzed for each group of animals.  A,B)  MyHC fiber composition was determined for the  
Sirt1-/- animals both 3 (A) and 7 (B) days post-injury.  C,D)  MyHC fiber composition of the 
Sirt1+/+ animals was determined at both 3 (C) and 7 (B) days post-injury.  * P<.05 injured vs. 




Figure 5.  A,B) BrdU incorporation was determined in all of the animals at both 3 (A) and 7 (B) 
days post-injury.  Values are expressed as the quantity of BrdU-positive myonuclei per one-
hundred fibers.  # P<.05 injured vs. respective control.    
 
Figure 6.  A,B) Apoptosis was assessed via TUNEL staining in all of the animals at both 3 (A) 
and 7 (B) days post-injury.  The TUNEL index is expressed as the quantity of TUNEL-positive 
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  The main objective of this thesis project was to examine the role of Sirt1 in skeletal 
muscle regeneration.  For this, we included two specific aims and each required a separate 
study to address the hypotheses.  We employed both nutritional and genetic techniques in an 
attempt to understand the effects of Sirt1 modulation on the regeneration of skeletal muscle in 
response to a perturbation in homeostasis.  Our hope was to advance the field of muscle 
regeneration and provide novel avenues to address this issue. 
 
Specific aim 1  
Our first specific aim utilized resveratrol, a known Sirt1 activator, as a nutritional 
supplement in an attempt to improve muscle regeneration in aged rats following a period of 
disuse.  We had hypothesized that resveratrol would improve regeneration (morphological 
and/or functional characteristics) in these animals by reducing mitochondrial-associated 
apoptosis, preserving muscle mass, and increasing the activation of satellite cells during a 
period of reloading which immediately followed disuse.   
 The results from this study provided evidence that resveratrol may provide a modest 
benefit in regenerating muscles of aged animals.  Although it proved ineffective at attenuating 
bodyweight and muscle mass decreases due to mechanical unloading, resveratrol was able to 
provide partial protection from the accompanying decrease in myofiber area in type II MyHC 
fibers.  Moreover, resveratrol did not statistically increase the activation of satellite cells as 
indicated by a similar quantity of BrdU-labeled myonuclei during the reloading period in vehicle 
and resveratrol treated animals. Nevertheless, resveratrol increased the relative protein 
abundance of the anti-apoptotic Bcl-xL protein during the suspension period, which may have 
contributed to the slight protection against myofiber area reductions observed in these animals.  
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Therefore, the attenuation of myofiber area loss during HS and reloading combined with the 
beneficial effects on apoptotic signaling lead us to conclude that resveratrol supplementation 
may be useful as a potential therapy to counteract muscle loss and improve regeneration in 
aged muscles in response to extended periods of disuse. 
 One obvious aspect of this study that could be manipulated in future research is the 
dose of resveratrol utilized.  In our study, we used 125 mg/kg/day, and this dose provided subtle 
benefits during unloading and reloading of skeletal muscle.  However, this dose could be 
increased substantially in order to determine if this will maximize the potential benefits of this 
supplement.  It is possible that by increasing the dose of resveratrol, satellite cells would be 
activated to a larger degree, thereby improving muscle size and possibly function.  Therefore, 
future research should attempt to determine the optimal dose of resveratrol to maximize its 
beneficial effects.  Moreover, although our current study was specifically conducted to 
determine resveratrol’s effectiveness in aged animals, future studies could utilize younger 
animals in order to maximize any potential responses, as these animals have much higher 
regenerative abilities. 
 
Specific aim 2 
 The main objective of the second aim was to directly examine the role of Sirt1 
expression on muscle regeneration in older-age adult mice.  In order to accomplish this, two 
separate transgenic lines of mice were utilized which presented either the knockdown of Sirt1 
expression (Sirt1-/-) or the overexpression of Sirt1 (Sirt1+/+).  We injured the animal’s muscles 
with an acute myotoxin injection and subsequently analyzed the muscle regeneration 
characteristics at both 3 and 7 days post-injury.   
 Overexpression of Sirt1 did not improve muscle mass or fiber area in regenerating 
muscles at either 3 or 7 days, nor was it detrimental for these measures when Sirt1 expression 
was decreased in the Sirt1-/- animals.  However, it was determined that increasing Sirt1 
116 
 
expression was beneficial to muscle force.  Following muscle injury, the maximal tetanic force 
produced in the muscles of the Sirt1+/+ animals was no different than that of the uninjured 
control muscles at both 3 and 7 days post-injury.  This is in contrast to the Sirt1+/+ WT animals, 
whose maximal tetanic force still had not recovered by day 7 post-injury.  Thus, we concluded 
from this study that increasing Sirt1 may be beneficial to muscle regeneration in that it improved 
muscle function (i.e., maximal tetanic force) which is very important in various clinical situations. 
 One possible explanation for the lack of increase in activation of satellite cells in Sirt1+/+ 
animals is that the rate of satellite cell activation was already at the maximal rate in the CTX 
model of severe damage and recovery. If that was the case, then additional intervention could 
not have increased the activation of satellite cells. To test this hypothesis, we would require an 
approach that would titrate the injury stimulus (e.g., stretch induced injury), and then evaluate if 
Sirt1+/+ mice had a greater activation of satellite cells in a less severe injury. 
 As this study examined muscle regeneration in an almost exclusively fast muscle (tibialis 
anterior), future research should be directed at examining the role of Sirt1 in muscle 
regeneration in other muscle types such as the slow-twitch soleus muscle, in order to establish 
whether Sirt1 may be more beneficial in certain fiber types.  Thus, it is possible that this study 
could be repeated in the future, but with the injury being directed towards a different muscle with 
alternate fiber types.  This may lead to therapies utilizing Sirt1 that are specialized for varying 
clinical conditions.   
 
A look to the future  
 Herein we provide support for the beneficial role of Sirt1 in skeletal muscle regeneration.  
Undertaking two separate studies with various muscle perturbations to address our specific 
aims, our hypotheses from each specific aim were confirmed as Sirt1 attenuated decreases in 
myofiber area in response to disuse and improved muscle force during the early stages of 
regeneration.  While far from complete, our research provides a positive base for future 
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research to examine the role and potential benefits of Sirt1 in varying clinical conditions as a 
novel therapeutic intervention.  Many diseases and conditions require some form of skeletal 
muscle maintenance and regeneration and therapies must be targeted to individualized 
circumstances.  Although our research did not yield any astonishing results to revolutionize the 
field, we have provided sufficient evidence to warrant future research into the study of the 
utilization of Sirt1 as a therapeutic to improve skeletal muscle regeneration in various 
conditions.  Only time may reveal the full impact of these findings and the extent to which they 
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